よくわかる乳癌のすべて

出版社： 永井書店
著者：
発行日： 2006-06-10
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 4815917558
電子書籍版： 2006-06-10 （第1版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

15,400 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

本書の主な読者対象としては、乳腺専門医を目指す医師をはじめ、研修医、開業医、看護師、薬剤師、検査技師、MRなどを想定している。さらに患者やその家族に説明する場合の資料提供として図表を用いたり、または患者や家族が直接読んでもわかるような内容となっている。

目次

  • よくわかる乳癌のすべて

    ―目次―

    1．乳癌診療の過去・現在・未来
    2．疫学
    3．診断
    4．病理
    5．分子生物学的特徴
    6．手術療法
    7．薬物療法
    8．放射線療法
    9．乳がん検診
    10．乳癌診療におけるインフォームド・コンセント
    11．チーム医療と緩和ケア
    12．病期分類および治療効果判定
    13．特別企画

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 乳癌診療の過去・現在・未来

P.14 掲載の参考文献
1) 財団法人厚生統計協会:国民衛生の動向, 厚生の指標. 臨時増刊52 (9):2005.
 
2) 厚生労働省がん研究助成金「地域がん登録研究班」:がん・統計白書; 罹患/死亡/予後.大島 明, 黒石哲生, 田島和雄 (編), pp 97-160, 篠原出版新社, 東京, 2004.
 
3) Veronesi U, Cascinelli N, Mariani L, et al:Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002.
PubMed
4) Fisher B, Anderson S, Bryant J, et al:Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002.
PubMed
5) 園尾博司:乳房温存療法; その現況と最近の考え方. ホルモンと臨床52 (7):703-708, 2004.
 
6) The Japanese Breast Cancer Society:Results of questionnaires concerning breast cancer surgery in Japan 1980-2003. Breast Cancer 12:1, 2005.
 
7) 稲治英生, 孤池佳史, 柄川千代美, ほか:乳房温存療法後の乳房内再発とその治療. 乳癌の臨床19 (6):533-538, 2004.
 
8) Kurtz JM, Jacquemier J, Amalric R, et al:Is breast conservation after local recurrence feasible? Eur J Cancer 27:240-244, 1991.
PubMed
9) 中島一毅, 園尾博司:これからの乳癌診療. 治療学39 (2):182-186, 2005.
 
10) Buzdar AU, et al:ASCO:#520, 2004.
 
11) 野口昌邦:乳癌外科の最前線. 金原出版, 東京, 2004.
 
12) 丹黒 章, 山本 滋, 長島由紀子, ほか:センチネルリンパ節生検の現況と問題点. 内分泌外科21 (4):247-253, 2004.
 
13) Gershon-Cohen J:Occult Carcinoma of Breast. Arch Surg 70:385, 1955.
PubMed
14) Leborgne R:Diagnosis of Tumors of the Breast by Simple Roentgenography; Calcification in Carcinoma. AJR 65:1-11, 1951.
 
15) Egan RL:Mammography. Thomas CC (ed), pp 99-304, Springfield, IL, 1964.
 
16) 久道 茂, ほか:新たながん検診手法の有効性の評価報告書. pp 1-16, 日本衛生協会, 東京, 2001.
 
17) 園尾博司:乳がん検診の有用性. 性差と医療1 (2):153-157, 2004.
 
18) 岡崎邦泰, 山本泰久, 園尾博司, ほか:岡山県の新しい乳癌検診指針について. 日乳癌検診学会誌14 (2):129-135, 2005.
 
19) 植野 暎, 伊藤吾子:超音波診断の新しい流れ. 乳癌の最新医療, 小山博記, 霞 富士雄 (監修), pp 93-98, 先端医療技術研究所, 東京, 2003.
 
20) 中村清吾:乳癌の診断と治療. 日臨58:61-65, 2000.
 
21) 山本 裕, 紅林淳一, 園尾博司, ほか:原発乳癌における乳房造影MRI検査の有用性と生物学的バックグラウンドに関する検討. 乳癌の臨床17:132-136, 2002.
 
22) Akashi-Tanaka S, Fukutomi T, Sato N, et al:The use contrast-enhanced computed tomography before neo adjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann Surg 239 (2):238-243, 2004.
 
23) 正津 晃:PET. 乳癌の最新医療, 小山博記, 霞富士雄 (監修), pp 103-109, 先端医療技術研究所, 東京, 2003.
 
24) 高橋かおる, 五味直哉, 坂元吾偉, ほか:Mammotome. 乳癌の最新医療, 小山博記, 霞 富士雄 (監修), pp 117-123, 先端医療技術研究所, 東京, 2003.
 
25) 園尾博司, 妹尾亘明:乳癌のホルモン療法; 総論.乳癌の臨床1 (2):165-179, 1987.
 
26) 園尾博司:術後補助ホルモン療法; 適応とその考え方. ナースのための最新乳癌テキスト, 内田 賢, 秋山 太 (編), pp 107-120, 真興交易医書出版部, 東京, 2003.
 
27) 園尾博司, 紅林淳一:進行・再発乳癌のホルモン療法. 癌と化療28:909-916, 2001.
 
28) 園尾博司:乳癌における薬物療法の現況. 臨床と研究80:1238-1244, 2003.
 
29) 園尾博司:ホルモンレセプター (ER, PgR) 測定の意義 日本臨床58 (増刊):146-153, 2000.
 
30) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting high [ights; International consensus panel on the treatment of primary breast cancer. J Clin Oncol 19 (18):3817-3827, 2001.
 
31) 園尾博司:乳癌とホルモン. 産婦人科治療87 (6):619-625, 2003.
 
32) Early Breast Cancer Trialists'Collaborative Group:Effectors of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer:An overview of 61 randomized trials among 28, 896 women. N Engl J Med 319:1681-1692, 1988.
 
33) Early Breast Cancer Trialists'Collaborative Group:Tamoxifen for early breast cancer:An overview of the randomized trials. Lancet 351:1451-1467, 1998.
 
34) Jonat W, Kaufmann M, Sauerbrei W, et al:Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer. J Clin Oncol 20:4628-4635, 2002.
PubMed
35) Jakesz R, Hausmaninger H, Kubista E, et al:Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil; Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol 20:4621-4627, 2002.
 
36) Love RR, Duc NB, Havighurst TC, et al:HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453-457, 2003.
PubMed
37) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights; International consensus on the primary therapy of early breast cancer. Annals of Oncology 16 (10):1569-1583, 2005.
PubMed
38) Baum M, Buzdar AU, Cuzick J, et al:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:first results of the ATAC randomized trial. Lancet 359:2131-2139, 2002.
PubMed
39) Coombes RC, Hall E, Gibson LJ, et al:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
PubMed
40) Goss PE, Ingle JN, Martino S, et al:A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1798, 2003.
 
41) Bonadonna G, Brusamolino E, Valagussa P, et al:Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976.
PubMed
42) Early Breast Cancer Trialists'Collaborative Group:Polychemotherapy for early breast cancer:an overview of the randomized trials. Lancet 352:930-942, 1998.
 
43) 園尾博司:術後ホルモン療法の適応と標準的レジメン. 臨床外科59 (9):115-158, 2004.
 
44) 日本乳癌学会 (編):乳癌診療ガイドライン, 1. 薬物療法. 金原出版, 東京, 2004.
 
45) Talbot DC, Moiseyenko V, Van Belie S, et al:Randomized, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. British J of Cancer 86 (9):1367-1372, 2002.
 
46) O'Shaughnessy J, Miles D, Vukelja S, et al:Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer; phase III trial results. J Clin Oncol 20 (12):2812-2823, 2002.
PubMed
47) Torrecillas L, et al:The 26th San Antonio Breast Cancer Symposium. 2004.
 
48) Noguchi S, Koyama H, Uchino J, et al:Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer:A pooled analysis of six randomized controiled trials. J Clin Oncol 23 (10):2172-2184, 2005.
PubMed
49) Fumoleau P, Delgado FM, Delozier T, et al:Phase III trial of weekly intravenous vinorelbine in firstline advanced breast cancer chemotherapy. J Clin Oncol 11:1245-1252, 1993.
 
50) 遠山達也, 岩田広治:Vinorelbine. 乳癌の臨床20 (3):186-195, 2005.
 
51) Tominaga T, Nomura Y, Adachi I, et al:Late phase II study of KW-2307 in advanced or recurrent breast cancer; KW-2307 Cooperative Study Group (Breast Cancer Section). Gan To Kagaku Ryoho 21:809-816, 1994.
PubMed
52) Chan L, Untch M, Petruzelka L, et al:Long term survival of vinorelbine and trastuzumab as first line therapy for HER 2-positive metastatic breast cancer patients. ASCO:#587, 2005.
 
53) 小林隆之, 高橋俊二, 伊藤良則:Carboplatin. 乳癌の臨床20 (3):196-205, 2005.
 
54) Martine J P-G, Piccart G, Marion P, et al:Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005.
 
55) Slamon DJ, Leyland-Jones B, Shak S, et al:Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344:783-792, 2001.
 
56) Blackwell KL, Kaplan EH, Franco SX, et al:A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Annu Meet Am Soc Clin Oncol 22 (14S):3006, 2004.
 
57) Fisher B, Constantino JP, Wickerham L, et al:Tamoxifen for prevention of breast cancer; Report of the National Surgical Adjuvant Breast and Bowel Project P-lstudy. J Natl Cancer Inst 90:1371-1388, 1998.
 
58) Cummings SR, Eckert S, Krueger KA, et al:The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189-2197, 1999.
PubMed

II. 疫学

P.28 掲載の参考文献
1) 厚生労働省大臣官房統計情報部人口動態・保健統計課:平成15年人口動態統計(確定数)の概況 (http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakuteiO3/index.html).
 
2) Research Group for Population-based Cancer Registration in Japan:Cancer incidence and incidence rates in Japan in l 999:Estimates based on data from II population-based cancer registries. Jpn J Clin Oncol 33:241-245, 2003 (http://www.mc.pref.osaka.jp/ocr/ocr_hcr/registry/statistics/incidence/incidence.html).
 
3) 大阪府健康福祉部, 大阪府医師会, 大阪府立成人病センター:大阪府におけるがん登録第68報. 大阪府, 2005 (http://www.mc.pref.osaka.jp/ocr/ocr-hcr/ocr/nenpo/nenpo68.pdf).
 
4) 厚生労働省大臣官房統計情報部 (編):平成12年都道府県別年齢調整死亡率. 人口動態特殊報告, 2002.
 
5) 厚生労働省大臣官房統計情報部 (編):平成7年都道府県別年齢調整死亡率. 人口動態特殊報告, 1997.
 
6) Ferlay J, Bray F, Pisani P, et al:GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, version 2.0, IARC, Lyon, 2004.
 
7) Parkin DM, Whelan SL, Ferlay J, et al (eds):Cancer Incidence in Five Continents. Vol. VHI, IARC Scientific Publications No. 155, IARC, Lyon, 2002.
 
8) Tajima N, Tsukuma H, Oshima A:Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol 1:1-7, 2001.
PubMed
9) 日本がん疫学研究会がん予防指針検討委員会:生活習慣と主要部位のがん. 「食物.栄養とがん予防」の日本人への適用性, 世界がん研究基金/米国がん研究協会 (編), 九州大学出版会, 福岡, 1998.
 
10) 黒石哲生:重要疾患の疫学と予防. 主要部位のがん, 乳がん. 疫学ハンドブック, 日本疫学会 (編), pp 42-46, 南江堂, 東京, 1998.
 
11) 広瀬かおる:乳癌のリスクファクターと予防. 乳癌の最新医療, 先端医療シリーズ21, 癌, 小山博記, 霞 富士夫 (監修), pp 358-364, 先端医療技術研究所, 東京, 2003.
 
12) 永田知里:乳がん. がん予防の最前線 (上), 田島和雄 (監修), pp 82-87, 昭和堂, 京都, 2004.
 
13) Tamakoshi K, Yatsuya H, Wakai K, et al for the JACC Study Group:Impact of menstrual and reproductive factors on breast cancer risk in Japan:Results of the JACC study. Cancer Science 96:57-63, 2005.
 
14) Yamamoto S, Sobue T, Kobayashi M, et al; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group:Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95:906-913, 2003.
PubMed
15) Hirose K, Hamajima N, Takezaki T, et al:Physical exercise reduces risk of breast cancer in Japanese women. Cancer Sci 94:193-199, 2003.
PubMed
16) Hirose K, Takezaki T, Hamajima N, et al:Dietary factors protective against breast cancer in Japanese premenopausal and postmenopausal women. Int J Cancer 107:276-282, 2003.
PubMed
17) Hamajima N, Hirose K, Tajima K, et al:Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer 87:1234-1245, 2002.
PubMed
18) Hanaoka T, Yamamoto S, Sobue T, et al; Japan Public Health Center-Based Prospective Study on Cancer and Cardiovascular Disease Study Group:Active and passive smoking and breast cancer risk in middle-aged Japanese women. Int J Cancer 114:317-322, 2005.
 
19) Tung HT, Tsukuma H, Tanaka H, et al:Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history. Jpn J Clin Oncol 29:137-146, 1999.
PubMed
20) Hirose K, Tajima K, Hamajima N, et al:A large-scale hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 86:146-154, 1995.
PubMed
21) Wakai K, Ohno Y, Watanabe S, et al:Risk factors for breast cancer among Japanese women in Tokyo; A case-control study. J Epidemiol 4:65-71, 1994.
 
22) Nagao Y, Kawaguchi Y, Sugiyama Y, et al:Relationship between mammographic density and the risk of breast cancer in Japanese women ; a case-control study. Breast Cancer 10:228-233, 2003.
PubMed
23) Preston DL, Mattsson A, Holmberg E, et al:Radiation effects on breast cancer risk; a pooled analysis of eight cohorts. Radiat Res 158:220-235, 2002.
 
24) La Vecchia C:Estrogen and combined estrogen-progestogen therapy in the menopause and breast cancer. Breast 13:515-518, 2004.
PubMed
25) Ueda K, Tsukuma H, Tanaka H, et al:Estimation of individualized probabilities of developing breast cancer for Japanese women. Breast Cancer 10:54-62, 2003.
PubMed
26) 大野ゆう子, 中村 隆, 村田加奈子, ほか:日本のがん罹患の将来予測:ベイズ型ポワソン・コウホートモデルによる解析に基づく2020年までの将来推計. がん・統計白書;罹患/死亡/予後/2004, 大島 明, 黒石哲生, 田島和雄 (編), pp 201-217, 篠原出版新社, 東京, 2004.
 
P.39 掲載の参考文献
1) 野水 整, 土屋敦雄, 渡辺文明, ほか:家族性乳癌の臨床. 家族性乳癌, 阿部力哉 (監修), pp 7-16, 篠原出版新社, 東京, 1996.
 
2) 野水 整, 阿部力哉:乳癌多発家系;家族性乳癌の臨床的検討. 癌の臨床33:477-481, 1987.
 
3) 土屋敦雄, 阿部力哉, 野水 整ほか:遺伝性乳癌の全国調査家族性乳癌, 阿部力哉 (監修), pp 17-34, 篠原出版新社, 東京, 1996.
 
4) Katagiri T, Kasumi F, Yoshimoto M, et al:High proportion of missense mutation of the BRCA I and BRCA 2 genes in Japanese breast cancer families. J Hum Genet 43:42-48, 1998.
 
5) Nomizu T, Tsuchiya A, Kanno M, et al:Clinicopathological features of hereditary breast cancer. Breast Cancer 4:239-242, 1997.
PubMed
6) Noguchi S, Kasugai T, Miki Y, et al:Clinicopathologic analysis of BRCA I-or BRCA 2 associated hereditary breast carcinoma in Japanese women. Cancer 85:2200-2205, 1999.
 
7) Sakayori M, Kawahara M, Shiraishi K, et al:Evaluation of the diagnostic accuracy of the stop codon (SC) assay for identifying protein-truncating mutations in the BRCA I and BRCA 2 genes in familial breast cancer. J Hum Genet 48:130-137, 2003.
 
8) Takeda M, Ishida T, Ohnuki K, et al:Collaboration of Breast Cancer Clinic and Genetic Counseling Division for BRCA I and BRCA 2 Mutation Family in Japan. Breast Cancer 11:30-32, 2004.
 
9) Kawahara M, Sakayori M, Shiraishi K, et al:ldentification and evaluation of 55 genetic variations in the BRCA I and the BRCA 2 genes of patients from 50 Japanese breast cancer families. J Hum Genet 49:391-395, 2004.
 
10) 三好康雄, 野口眞三郎:BRCA1, BRCA2乳癌の臨床病理学的特徴. 乳癌の最新医療, 小山博記, 露富士雄 (監修), pp 164-174, 先端医療技術研究所, 東京, 2003.
 
11) Miki Y, Swensen J, Shattuck-Eidens D, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRC41. Science 266:66-71, 1994.
 
12) Wooster R, Bignell G, Lancaster J, et al:ldentification of the breast cancer susceptibility gene BRC42. Nature 378:789-792, 1995.
 
13) lshioka C, Suzuki T, FitzGerald M, et al:Detection of heterozygous truncating mutations in the BRCAIand APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci USA 94:2449-2453, 1997.
 
14) Turner BC, Harrold E, Matloff E, et al:BRC4//BRC42 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy; implications for breast-conserving man. agement in patients with BRCA//8RCA2 mutations. J Clin Oncol 17:3017-3024, 1999.
 
15) Haffty BG, Harrold E, Khan AJ, et al:Outcome of conservatively managed early-onset breast cancer by BRCA//2 status. Lancet 359:1471-1477, 2002.
 
16) 阿部力哉, 佐藤寿雄, 吉田弘一, ほか:乳癌の集団検診; 早期発見の試み. 日外会誌86:941-947, 1985.
 
17) Fisher B, Costantino JP, Wickerham DL, et al:Tamoxifen for prevention of breast cancer I Report of the National Surgical Adjuvant Breast and Bowel Project P-r Study. J Natl Cancer Inst 90:1371-1388, 1998.
 
18) Hartmann LC, Schaid DJ, Woods JE, et al:Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340:77-84, 1999.
PubMed
19) Rebbeck TR, Levin AM, Eisen A, et al:Breast cancer risk after bilateral prophylactic oophorectomy in BRC4/mutation carriers. J Natl Cancer Inst 91:1475-1479, 1999.
 
20) Lynch HT, Watson P, Narod S, et al:An update on DNA-based BRCA 1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109:91-98, 1999.
 
21) 野水 整, 伊藤康平:家族性乳癌, 予防. 日本臨牀 58 (増刊号):537-541, 2000.
 
22) 三好康雄, 野口眞三郎:家族性乳癌の診断と治療. 癌と化療29:512-522, 2002.
 

III. 診断

P.50 掲載の参考文献
1) 日本乳癌学会 (編):乳癌取扱い規約. 第15版, 金原出版, 東京, 2004.
 
2) Sobin LH, Wittekind Ch (eds):International Union Against Cancer. TNM Classification of Malignant Tumors, 6th ed, pp 131-141, Wiley-Liss, New York, 2002.
 
3) Russo J, Hu YF, Silva ID, et al:Cancer risk related to mammary gland structure and development. Microsc Res Tech 52:204-223, 2001.
PubMed
4) 田久保海誉:高齢者・超高齢者の乳腺症乳腺症.乳腺症の臨床; その概念と診療のためのアトラス, 坂元吾偉 (監修), 日馬幹弘, ほか (編), pp 37-43, 篠原出版新社, 東京, 1997.
 
5) Hughes LE, Mansel RE, Webster DJ:Aberrations of normal development and involution (ANDI); a new perspective on pathogenesis and nomenciature of benign breast disorders. Lancet 8571:1316-1319, 1987.
 
P.58 掲載の参考文献
1) 石田常博:乳癌の診断. 最新・乳癌の診断と治療, 第2版, 泉雄 勝 (編), pp 82-90, 永井書店, 大阪, 1997.
 
2) 横江隆夫:視触診. 乳癌の診療:基礎と臨床, 第1版, 飯野佑一(編), pp 14-17, メディカルレビュー, 東京, 2002.
 
P.89 掲載の参考文献
1) 植野 映:リアルタイム乳房超音波診断. 南江堂, 東京, 1991.
 
2) Ueno E, Tohno E, ltoh K:Classification and diagnostic criteria in breast echography. Jpn J Med Ultrasonics 13:19-31, 1986.
 
3) Endo T, Kubota M, Konishi Y, et al:Diagnostic Guidelines for Non Mass image-Forming Lesions by the Japan Association of Breast and Thyroid Sonology (JABTS) and the Japan Society of Ultrasonics in Medicine Research and Development in Breast Ultrasound. Ueno E, Shiina T, Kubota M, et al (eds), pp 89-100, Springer, Tokyo, 2005.
 
4) Ueno E, Endo T, Kato Y, et al:Draft JSUM Diagnostic Guideline for Mass lmage-Forming Lesions. Research and Development in Breast Ultrasound, Ueno E, Shiina T, Kubota M, et al (eds), pp 76-88, Springer-Verlarg, Tokyo, 2005.
 
5) Tsunoda-Shimizu H, Kato Y, Ueno E, et ai:Usefulness of Depth to Width Ratio in Differentiation of Regular Invasive Ductal Carcinoma from Fibroadenomas. Research and Development in Breast Ultrasound, Ueno E, Shiina T, Kubota M, et al (eds), pp 57-61, Springer-Verlarg, Tokyo, 2005.
 
6) Morishima I, Ueno E, Tohno E, et al:Ultrasonic Diagnosis of Non-mass lmage Forming Breast Cancer Research and Development in Breast Ultrasound. Research and Development in Breast Ultrasound, Ueno E, Shiina T, Kubota M, et al (eds), pp 127-134, Springer, Tokyo, 2005.
 
7) Kujiraoka Y, Ueno E, Tohno E, et al:Incident angle of the plunging artery of breast tumors. Research and development in breast ultrasound, Ueno E, Shiina T, Kubota M, et al (eds), pp 72-75, Springer-Verlarg, Tokyo, 2005.
 
8) Shiina T, Ueno E,:In vivo breast examination by real-time freehand elasticity imaging system. Research and development in breast ultrasound, Ueno E, Shiina T, Kubota M, et al (eds), pp 7-15, Springer-Verlarg Tokyo, 2005.
 
9) Ueno E, ltoh A:Diagnosis of breast cancer by elasticity imaging. Eizo Joho Medical 36:2-6, 2004.
 
P.100 掲載の参考文献
1) 吉本賢隆,岩瀬拓士, ほか:乳癌のサブトラクションMRI. 医学の歩み162 (13):951-952, 1992.
 
2) 吉本賢隆:乳癌MRI診断法の進歩. 乳癌の臨床8 (4):535-545,1993.
 
3) 堀 文子, 吉本賢隆, ほか:Breast MRIにおけるsubtractionおよびfat suppression画像の比較検討. 第9回日本乳癌学会総会 プログラム・抄録集p 177, 2001.
 
4) 堀 文子,吉本賢隆, ほか:乳癌術前化学療法におけるMRIの画像変化と有用性. 日本外科学会雑誌102 (臨時増刊号):243, 2001.
 
5) 堀 文子, 坂元吾偉, ほか:乳癌術前Weekly Taxol療法におけるMR画像診断の有用性. 日本外科学会雑誌104 (臨時増刊号):515, 2003.
 
6) 堀 文子, 坂元吾偉, ほか:乳癌術前Weekly Taxol療法の効果判定におけるMR画像診断の有用性,第11回日本乳癌学会総会 プログラム・抄録集p 115, 2003.
 
7) 堀 文子:乳房MRI指南書. 第1版, メジカルビュー社, 東京, 2005.
 
P.107 掲載の参考文献
1) Akashi-Tanaka S, et al:Diagnostic value of contrast-enhanced computed tomography for diagnosing the intraductal component of breast cancer. Breast Cancer Res Treat 49:79-86, 1998.
PubMed
2) Akashi-Tanaka S, et al:The role of computed tomographyin the selection of breast cancer treatment. Breast Cancer 10 (3):198-203, 2003.
 
3) Uematsu T, et ai:Value of Three-Dimensional Helical CT image-Guided Planning for Made-to-Order Lumpectomy in Breast Cancer Patients. Breast J IO (1):33-37, 2004.
 
4) 明石定子:CT. 悪性と間違えやすい乳腺の良性病変, 第1版, 坂元吾偉, 芳賀俊介 (監修), pp 117-126, 篠原出版新社, 東京, 2004.
 
5) 明石-田中定子:術前化学療法と手術術式. 臨床外科57 (3):335-339, 2002.
 
6) Akashi-Tanaka S, et al:Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy. Int J Cancer 96 (1):66-73, 2001.
PubMed
7) Akash卜Tanaka S, et al:The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery. Ann Surg 239 (2):238-243, 2004.
 
8) 枝園忠彦, ほか:MD-CTにおける乳癌の組織型と腋窩リンパ節転移の形状と造影効果の検討. 日外会誌106:198, 2005.
 
9) Nakahara H, et al:Extension of breast cancer; comparison of CT and MRI. Radiat Med 20 (1):17-23, 2002.
PubMed
P.114 掲載の参考文献
1) Conney EC, Geraghty JG, O'Laoide R, et al:Reasons underlying negative mammography in patients with palpable breast cancer. Clin Radiol 49:123-125, 1994.
 
2) Waxman AD, Ramanna L, Memsic LD, et al:Thallium scintigraphy in the evaluation of mass abnormalities of the breast. J Nucl Med 34:18-23, 1993.
PubMed
3) Campeau RJ, Kronemer KA, Shuterland CM:Concordant uptake of Tc-99 m sestamibi and Tl-201 in unsuspected breast tumor. Clin Nucl Med 17:936-937, 1992.
 
4) Khalkhali I, Cutrone JA, Mena IG, et al:Scintimmanography; The complementary role of Tc-99 m sestamibi prone breast imaging for the diagnosis of breast carcinoma. Radiology 196:421-426, 1995.
 
5) Taillefer R, Robidoux A, Lambert R, et al:Tc-99 m sestamibi prone scintigraphy to detect primary breast cancer and axillary lymphnode involvement. J Nucl Med 36:1758-1765, 1995.
 
6) Tiling R, Kessler M, et al:Initial evaluation of breast cancer using Tc-99 m sestamibi scintimammography. Eur J Radiol 53:206-212, 2005.
 
7) Wilczek B, Svensson L, Danielsson R, et al:99mTc-exametazime as a breast tumor-seeking agent; comparison with 99mTc-sestamibi. J Nucl Med 45:2040-2044, 2004.
PubMed
8) Oriuch N, Jibu T, Milas L, et al:Assessment of resistance to paclitaxel of murine tumors by 99mTc-MIBI/201TI dual-radionuclide imaging. Nucl Med Biol 27:127-133, 2000.
 
9) Rhodes DJ, O'connor MK, Phillips SW, et al:Molecular breast imaging:a new technique using technetium tc-99 scintimammography to detect small tumors of the breast. Obstet Gynecol Surv 60:312-314, 2005.
 
10) DiChiro G, DeLaPaz RL, Brooks RA, et al:Glucose utilization of cerebral gliomas measured by (18) fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329, 1982.
 
11) Wahl RL, Cody RL, Hutchins GD, et al:Primary and metastatic breast carcinoma; initial clinical evaluation with PET with the radiolabeled glucose analogue 2-F-18-fluoro-2-deoxy-D-glucose. Radiology 179:765-770, 1991.
PubMed
12) Tse NY, Hoh CK, Hawkins RA, et al:The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast cancer. Ann Surg 216:27-34, 1992.
 
13) Eubank WB, Mankoff DA:Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med 35:84-99, 2005.
PubMed
14) Carer CL, Allen C, Hensen DE:Relation of tumor size, lymphnode status, and survival in 24, 740 breast cancer cases. Cancer 63:181-187, 1989.
 
15) Arvil N, Dose j, Janicke F, et al:Assessment of axillary lymphnode involvement in breast cancer patierlts with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88:1204-1209, 1996.
 
16) Avril N, Ros CA, Schelling M, et al:Breast imaging with positron emission tomograohy and fluorine-18fluorodeoxyglucose; use and limitations. J Clin Oncol 18:3495-3502, 2000.
 
17) Lee PA, Faulhaber PF, Schnur KC, et al:Axillary lymphnode metastases:Screening with [F-18] 2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203:323-327, 1997.
 
18) Bellon JR, Livingston RB, Eubank WB, et al:Evaluation of the internal mammary lymphnodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27:407-410, 2004.
 
19) Smith IC, Welch AE, Hutcheon AW, et al:Positron emission tomography using [F-18]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000.
PubMed
20) Schelling M, Avril N, Nahrig J, et al:Positron emission tomography using [F-18]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000.
PubMed
21) Kim SJ, Kim SK, Lee ES, et al:Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15:1352-1357, 2004.
PubMed
22) Cook GJ, Houston S, Rubens R, et al:Detection of bone metastasis in breast cancer by 18 FDG PET:differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998.
 
23) Uematsu T, Yuen S, Yukisawa S, et al:Comparison of FDG PET and SPECT for detection of bone metastasis in breast cancer. AJR Am J Roentgenol 184:1266-1273, 2005.
 
24) Kole AC, Nieweg KO, Prium J, et al:Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C] tyrosine PET. J Nucl Med 38:692-696, 1997.
 
25) Amano S, Inoue T, Tomiyoshi K, et al:In vivo comparison of PET and SPECT radiopharmaceutica is in detecting breast cancer. J Nucl Med 39:1424-1427, 1998.
 
26) Dehdashti F, Flanagan FL, Mortimer JE, et al:Positron emission tomographic assessment of "metabolic flare" to predict response of metabolic breast cancer to antiestrogen therapy. Eur J Nucl Med 26:51-56, 1999.
PubMed
27) Shields AF, Grierson JR, Dohmen BM, et al:Imaging proliferation in vivo with [F-18] FLT and positron emission tomography. Nat Med 4:1334-1336, 1998.
PubMed
P.122 掲載の参考文献
1) 蒔田益次郎:特集, 乳癌診療の最前線,乳管内視鏡診断. 癌の臨床46 (5):563-570, 2000.
 
2) 蒔田益次郎:目で見るカラーグラフ, 世界に向かう乳腺疾患診療の新技術, 4, 乳管微小病変の 乳管内視鏡分類. 臨外58 (8):1021-1028, 2003,
 
3) 蒔田益次郎, 秋山 太, 五味直哉, ほか:異常乳頭分泌を呈する乳管内病変の内視鏡所見と組織所見の対比. 乳癌の臨床19 (6):575-582, 2004.
 
4) 蒔田益次郎, 難波 清, 青山英子, ほか:異常乳頭分泌症例における乳管内病変の内視鏡診断;乳管内視鏡分類について. 乳癌の臨床11(1):134-141, 1996.
 
P.130 掲載の参考文献
1) 岡崎 稔, 岡崎 亮, 平田公一, ほか:MRI, 乳管内視鏡など新しい診断法の有用性. 乳房温存療法のすべて, 渡辺 弘 (監修), pp 62-67, メディカルビュー社, 東京, 1994.
 
2) 岡崎 稔, 岡崎 裕, 成松英明:穿刺吸引法による乳腺腫瘤の診断(1) 自動穿刺吸引塗抹装置の開発とその診断的意義.日臨外41:822-827, 1980.
 
3) 岡崎 亮, 岡崎 稔, 渡部芳樹, ほか:乳頭異常分泌症における乳管内病変の画像診断;特に乳管造影法と乳管内視鏡による乳管内病変の診断. 臨床画像19:964-977, 2003.
 
4) Zajdela A, Ghossein, NA, Pilleron JP:The value of aspiration cytlogy in the diagnosis of breast cancer:Experience at the foundation curie. Cancer 35:499-506, 1975.
 
5) 岡崎 稔, 岡崎 裕, 成松英明:穿刺吸引法による乳腺腫瘤の診断 (11) 各種疾患細胞における形態学的ならびに診断学的研究. 日臨外45:225-238, 1984.
 
6) 池永素子:細胞診による乳癌の早期診断.乳癌の最新医療.小山博記, 霞 富士雄 (監修), pp 45-48, 先端医療技術研究所, 東京, 2003.
 
7) 土屋眞一, 石原明徳:第IX章細胞診. 悪性と間違えやすい乳腺の良性疾患, 坂元吾偉,芳賀駿介 (監修), pp 135-155, 篠原出版新社, 東京, 2004.
 
P.138 掲載の参考文献
1) Krag D, Weaver D, Ashikaga T, et al:The sentinel node in breast cancer; A multicenter validation study. New Engl J Med 339:941-946, 1998.
PubMed
2) Pisano ED, Fajardo LL, Tsimikas J, et al:The Radiologic Diagnostic Oncology Group 5 Study:Rate of insufficient samples for fine-needle aspiration for nonpalpable breast lesions in a multicenter clinical trial. Cancer 82:679-688, 1998.
 
3) 日本乳癌学会 (編):乳腺における細胞診および針生検の報告様式ガイドライン. 第1版, 金原 出版, 東京, 2003.
 
4) Diaz LK, Wiley EL, Venta LA:Are malignant cells displaced by large-gauge needle core biopsy of the breast? Am J Roentgegnol 173:1303-1313, 1999.
 
5) Kurosumi M:Significance of histopathological evaluation in primary therapy for breast cancer; recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11:139-147, 2004.
PubMed
P.144 掲載の参考文献
1) Parker SH, Burbank F:A practical approach to minimally invasive breast biopsy. Radiology 200:11-20, 1996.
PubMed
2) 竹井淳子, 中村清吾:外科的生検法. 外科67:13-16, 2005.
 
3) Burbank F, Parker SH, Fogarty TJ:Stereotactic breast biopsy; improved tissue harvesting with the Mammotome. Am Surg 62:738-744, 1996.
PubMed
4) Burbank F:Stereotactic breast biopsy; comparison of 14-and II-gauge Mammotome probe performance and complication rates. Am Surg 63:988-995, 1997.
 
5) Berg WA, Krebs TL, Campassi C, et al:Evaluation of 14-and II-gauge directional, vacuum-assisted biopsy probes and 14-gauge biopsy guns in a breast parenchymal model. Radiology 205:203-208, 1997.
 
6) Fine RE, Whitworth PW, Kim JA, et al:Low-risk palpable breast masses removed using a vacuum-assisted hand-held device. Am Surg 186:362-367, 2003.
PubMed
7) Diaz LK, Wiley EL, Venta LA:Are malignant cells displaced by large-gauge needle core biopsy of the breast? AJR 173:1303-1313, 1999.
PubMed
8) 画像ガイド下乳腺針生検研究会:マンモトーム生検ガイドライン. 2003.
 
9) Liberman L, Sama MP:Cost-effectiveness of sterotactic II-gauge directional vacuum-assisted breast biopsy. AJR 175:53-58, 2000.
 
P.150 掲載の参考文献
1) 芳賀駿介, 今村 洋, 清水忠夫, ほか:乳房温存療法におけるlunpectomy. 外科診6 (41):717-721, 1994.
 
2) Brown TA, Wall JW, Christenson ED, et al:A typical hyperplasia In the era of stereotactic core needle biopsy. J Surg Onc 67 (3):168-173, 1998.
 
3) Sakorafas GH, Branchard K, Sarr MG, et al:Paget disease of the breast. Cancer treatment review 27 (1):9-18, 2001.
 
4) Magi AA, Smith BL, Gadd NA, et al:Surgical management of phyllodes tuworg. Achieves of Surgery 134 (5):487-492, 1999.
 
5) 服部孝雄, ほか:乳がんとbiopsy; 第30回乳癌研究会全国アンケートに関する研究. 癌の臨床 26:869-877, 1980.
 
6) 藤森 実, 千賀 脩, 寺井直樹, ほか:乳癌における生検の予後におよぼす影響. 日本外科学会雑誌88 (11):1619-1623, 1987.
 
7) Hoorntje LE, Schipper MEI, Kaya A, et al:Tumor cell displacement after 14G breast biopsy. Europian J Surg Onc 30 (5):520-525, 2004.
 
8) Donegan WL, Spratt JS:Cancer of the breast. 2nd ed, p 77, W. B. Saunders Co., Philadelphia, London, Toronto, 1979.
 
P.160 掲載の参考文献
1) 紅林淳一, 山本裕, 田中克浩, ほか:本邦における乳癌腫瘍マーカー測定の現状; 日本乳癌学会評議員を対象としたアンケート調査集計. 乳癌の臨床17:165-169, 2002.
 
2) Gold P, Freedman SO:Demonstration of tumor-specific antigens in human colonic carcinoma; By immunologic tolerance adsorption techniques. J Exp Med 121:439-466, 1965.
 
3) 園尾博司:第3章 乳癌の生物学4 乳癌と腫瘍マーカー. 図説臨床「癌」シリーズ乳癌, 杉村 隆 (監修), 末桝恵一, 高山昭三, 服部 信, ほか (編), pp 40-43, メジカルビュー社, 東京, 1993.
 
4) Hilkens J, et al:Monoclonal antibodies against human milkfat globle memnranes useful in human carcinoma research. Prot Biol Fluids 31:1013-1016, 1984.
 
5) Kufe D, et al:Differential reactivity of a novel monoclonal antibody (DF 3) with human malignant versus benign breast tumors. Hybridoma 3:223-232, 1984.
 
6) Bast RC, Ravdin P, Hayes DF, et al:2000 Update of recommendations for the use of tumor markers in breast and colorecta]cancer; clinical practice guidelines of the Amerlcan Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001.
 
7) Hirohashi S, et al:Monoclonal antibody reactive with the sialyl-sugar residue of a high molecular weight glycoprotein in sera of cancer patients. Gann 75:485-488, 1984.
PubMed
8) 山本 裕, 園尾博司, 木村 綾, ほか:乳癌における腫瘍マーカーNCC-ST-439の再発診断および偽陽性例の検討.乳癌の臨床16 (3):269-273, 2001.
 
9) 吉岡 久, 櫻林郁之介, 鈴木公明, ほか:癌関連糖鎖抗原NCC-ST-439に関する基礎的検討ならびに基準値の設定. 臨病理35 (11):1233-1238, 1987.
 
10) Bjorklund B, et al:Antigenecity of pooled human malignant and normal tissues by cytoimmunological technique; Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy 10:153-184, 1957.
 
11) Mesa-Tejada R, et al:Immunocytochemical distribution of a breast carcinoma associd glycoprotein identified by monoclonal antibodies. Am J Pathol 130:305-314, 1988.
PubMed
12) 石 和久, ほか:新しい腫瘍マーカーBCA 225の臨床応用に関する検討 (第1報). 臨床病理 37:301-305, 1989.
 
13) 杉山和義, ほか:乳癌における新しい腫瘍マーカーBCA 225の有用性の検討. 日臨外会誌51:1380-1388, 1990.
 
14) Goldhirsch A, Glick JH, Gelber RD, et al:meeting highlights; Internationai consensus on the primary therapy of early breast cancer. Annals of Oncology 16 (10):1569-1583, 2005.
 
15) 菅野康吉, 河合 忠, 石井 勝ほか:EIAキットによる血清Erb B 2の臨床的検討. 癌と化療 21:1255-1262, 1994.
 
16) Sugano K, Ushiama M, Fukutomi T, et al:Combined measurement of the c-erb B-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer (Pred Oncol) 89:329-336, 2000.
 
17) Wu JT:C-erbB 20ncoprotein and its soluble ectodomain; a new potential tumor marker for prognosis, early detection and monitoring patients undergoing Herceptin treatment. Clin Chim Acta 322:11-19, 2002.
 
18) Nakata B, Ogawa Y, lshikawa T, et al:Serum CYFRA 21-lis one of the most reliable tumor markers for breast carcinoma. Cancer 89:1285-1290, 2000.
 
19) Nakata B, Takashima T, Ogawa Y, et al:Serum CYFRA 21-1 (cytokeratin-19fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. British J Cancer 91:873-878, 2004.
 
20) 山本和子, 木村恒人, 宮川隆平, ほか:乳癌における腫瘍マーカーSialyl-LeXの臨床的意義.東京女子医科大学雑誌65 (臨時増刊):16-21, 1995.
 
21) 野村長久, 園尾博司, ほか:乳頭異常分泌の検討. 日本乳癌検診学会誌12:271-276, 2003.
 
22) 園尾博司:乳頭分泌液. 臨床検査ガイド2005～2006, Medical Practice編集委員会 (編), pp 964-967, 文光堂, 東京, 2005.
 
23) Inaji H, Koyama H, Motomura K, et al:ErbB-2 protein levels in nipple discharge; role in diagnosis of early breast cancer. Tumor Biol 14:271-278, 1993.
PubMed
24) Kurebayashi J, Nishimura R, Tanaka K, et al:Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy l a prospective study. Breast Cancer 11(4):389-395, 2004.
 
25) Kurebayashi J, Yamamoto Y, Tanaka K, et al:Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy; a large scale retrospective study. Breast Cancer 1O:38-44, 2003.
 
26) Gion M, Mione R, Leon AE, et al:Comparison of the diagnostic accuracy of CA 27. 29 and CA 15.3 in primary breast cancer. Clin Chem 45:630-637, 1999.
PubMed
27) 園尾博司:臓器別腫瘍マーカー5) 乳癌. 臨床検査33:1421-1425, 1989.
 
28) 日本乳癌学会 (編):乳癌診療ガイドライン4. 検診・診断2005年版, p 76, 金原出版, 東京, 2005.
 
29) 園尾博司, 妹尾亘明:乳癌の術後追跡. 乳癌の臨床167-180, 1989.
 
30) Suarez M, Perez-Castejon MJ, Jimenez A, et al:Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46:113-121, 2002.
PubMed
31) 紅林淳一:IV. 再発乳癌の治療2. 腫瘍マーカー. 最新・乳癌の診断と治療, 改訂第2版, 泉雄 勝 (編), pp 301-311, 永井書店, 大阪, 1990.
 
32) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000.
PubMed
33) Kiang DT, Greenberg LJ, Kennedy BJ:Tumor marker kinetics in the monitoring of breast cancer. Cancer 65:193-199, 1990.
PubMed
34) Sonoo H, Kurebayashi J:Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Jpn J Surg 26:250-257, 1996.
 

IV. 病理

P.170 掲載の参考文献
1) Hashizume K, Hatanaka Y, Kamihara Y, et al:inter laboratory Comparison in Hercep Test Assessment of HER 2 Protein Status in Invasive Breast Carcinoma Fixed With Various Formalin-based Fixatives. Applied lmmunohistochemistry & Molecular Morphology 11:339-344, 2003.
 
2) トラスツズマブ病理部会作成:HER2検査ガイド. 第2版, p 5, 中外製薬, 東京, 2003.
 
3) 日本乳癌学会 (編):乳癌取扱い規約. 第15版, pp 6-7, 金原出版, 東京, 2004.
 
P.183 掲載の参考文献
1) 坂本吾偉:病理組織学的にみた乳腺の「境界病変」. 病理と臨床10:882-886, 1992.
 
2) Koerner FC:Epithelial proliferations of ductal type. Semin Diagn Pathol 21 (1):10-17, 2004.
PubMed
3) Page DL, Rogers LW:Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Hum Pathol 23:1095-1097, 1992.
PubMed
4) Tavassoli FA:Ductal carcinoma in situ; introduction of the concept of ductal intraepithelial neo.plasia. Mod Pathol 11:140-154, 1998.
 
5) Tavassoli FA, Schnitt SJ, Hoefler H, et al:Intraductal proliferating lesions. Tumor of the breast and female genital organs, WHO classification of tumors, Fattaneth A, Tavassoli FA, Devilee P (eds), PP 63-73, IARC press, Lyon, 2003.
 
6) Oyama T, Maluf H, Koerner F:A typical cystic lobules; an early stage in the formation of low-grad ductal carcinoma in situ. Virchows Arch 435:413-421, 1999.
 
7) Page DL, Kidd TE Jr, Dupont WD, et al:Lobular neoplasia of the breast; higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22:1232-1239, 1991.
PubMed
8) Page DL, Jensen RA:Evaluation and management of high risk and premalignant lesions of the breast. World J Surg 18:32-38, 1994.
PubMed
P.194 掲載の参考文献
1) 日本乳癌学会 (編):乳腺腫瘍の組織学的分類. 臨床・病理乳癌取扱い規約, 第7版, 金原出版, 東京, 1984.
 
2) World Health Organization:Histo|ogical typing of breast tumours. 2nd ed, WHO, geneva, 1981.
 
3) Rosen PP, Oberman HA:Tumors of the mammary gland. Atlas of tumor pathology, AFPI, Washington DC, 1993.
 
4) World Health Organization:Pathology & genetics. Tumours of the breast and female genital organs, Tavassoli A, Devilee P (eds), WHO, Lyon, 2003.
 
5) Kurosumi M, Sugamata N, Tabei T:Prognostic significance of scoring system based on histological heterogeneity of invasive ductal carcinoma for node-negative breast cancer patients. Oncol Rep 10:833-837, 2003.
 
6) WHO CIassification of Tumours:Intraductal proliferative lesions. Pathology and Genetics:Tumours of the breast and female genital organs, pp 63-75, IARC Press, Lyon, 2003.
 
7) Fisher ER, Dignam J, Tan-Chiu E, et al:Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17; intraductal carcinoma. Cancer Aug 186 (3):429-438, 1999.
 
8) WHO CIassification of Tumours:Lobular neoplasia. Pathology and Genetics; Tumours of the breast and female genital organs, pp 60-62, IARC Press, Lyon, 2003.
 
9) WHO CIassification cf Tumours:Medullary carcinoma. Pathology and Genetics; Tumours of the breast and female genital organs, pp 28-29, IARC Press, Lyon, 2003.
 
10) WHO CIassification of Tumours:Invasive lobular carcinoma. Pathology and Genetics; Tumours of the breast and female genital organs, pp 22-26, IARC Press, Lyon, 2003.
 
11) WHO CIassification of Tumours:Squamous cell carcinoma. Pathology and Genetics; Tumours of the breast and female genital organs, pp 38-39, IARC Press, Lyon, 2003.
 
12) WHO CIassification of Tumours:Metaplastic carcinoma. Pathology and Genetics; Tumours of the breast and female genital organs, pp 37-41, IARC Press, Lyon, 2003.
 
13) Wick MR, Lillemoe TJ, Copland GT, et al:Gross cystic disease fluid protein-is as a marker for breast cancer; immunohistochemical analysis of 690 human neoplasma and comparison with alpha-lactoaibumin. Hum Pathol 20:281-287, 1989.
 
14) Leal C, Henrique R, Monteiro P, et al:Apocrine ductal carcinoma in situ of the breast:Histologic classification and expression of biologic markers. Hum Pathol 32:487-493, 2001.
PubMed
15) WHO CIassification of Tumours:Secretory carcinoma. Pathology and Genetics; Tumours of the breast and female genital organs, pp 42-43, IARC Press, Lyon, 2003.
 
16) WHO CIassification of Tumours:Invasive micropapillary carcinoma. Pathology and Genetics:Tumours of the breast and female genital organs, pp 35-36, IARC Press, Lyon, 2003.
 
17) Hull MT, Priest JB, Broadie TA, et al:Glycogen-rich clear cell carcinoma of the breast; alight and eiectron microscopic study. Cancer 48:2003-2009, 1981.
 
18) Wargotz ES, Norris HJ:Metaplastic carcinomas of the breast:1. Matrix-producing carcinoma. Hum Pathol 20:628-635, 1989.
 
P.203 掲載の参考文献
1) 日本乳癌学会 (編). 臨床・病理 乳癌取扱い規約. 第15版, 金原出版, 東京, 2004.
 
2) Kouno T, Shimizu C, Watanabe T, et al:A reliable nuclear grading system for primary breast cancer for selecting high risk invasive ductal carcinoma among node negative patients. Proc Am Soc Clin Oncol 22:29 (#113), 2003.
 
3) Yoshimoto M, Sakamoto G, Ohashi Y:Time dependency of the influence of prognostic factors on relapse in breast cancer. Cancer 72:2993-3001, 1993.
PubMed
4) Zhang G-J, Tsuda H, Adachi l, et al:Prognostic indicators of breast cancer patients with one to three regional lymph-node metastasis, with special reference to alterations in expression levels of bcl-2, p 53, and c-erbB-2 proteins. Jpn J Clin Oncol 27 (6):371-377, 1997.
 
5) Tsuda H, Hirohashi S:Multiple developmental pathways to highly aggresslve breast cancers disclosed by comparison of histologic grades and c-erbB-2expression patterns in both the intraductal and invasive portions. Pathol Int 48:518-525, 1998.
 
6) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights; international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569-1583, 2005.
PubMed
7) Tsuda H, Sakamaki C, Tsugane S, et al:Prognostic significance of histological grade and accumulation of gene and chromosome alterations in node-negative breast carcinoma. Jpn J Clin Oncol 28:5-11, 1998.
PubMed
8) Tsuda H, Takarabe T, Hirohashi S:Correlation of the numerical and structural status of chromosome 16with the histological type and grade of non-invasive and invasive breast carcinomas. Int J Cancer 84:381-387, 1999.
 
9) Tsuda H, Akiyama F, Kurosumi M, et al:The efficacy and limitations of repeated slide conferences for improving interobserver agreement when judging nuclear atypia of breast cancer. Jpn J Clin Oncol 29:68-73, 1999.
PubMed
10) Paik S, Shak S, Tang G, et al:A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004.
PubMed

V. 分子生物学的特徴

P.214 掲載の参考文献
1) Weidner N, Semple JP, Welch WR, et al:Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991.
PubMed
2) Perou CM, Sorlie T, Eisen MB, et al:Molecular portraits of human breast tumours. Nature 406:747-752, 2000.
PubMed
3) van't Veer LJ, Dai H, van de Vijver, et al:Gene expression profi|ing predicts clinical outcome of breast cancer. Nature 415:530-536, 2002.
 
4) Paik S, Shak S, Tang G, et al:A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-26, 2004.
PubMed
P.221 掲載の参考文献
1) Walter P, Green S, Greene G, et al:Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82:7889-7893, 1985.
PubMed
2) Kuiper GG, Enmark E, Pelto-Huikko M, et al:Cloning of a novel receptor expressed in rat prostate and ovary. Proc Nat|Acad Sci U S A 93:5925-5930, 1996.
PubMed
3) Bocchinfuso WP, Lindzey JK, Hewitt SC, et al:Induction of mammary gland development in estrogen receptor-alpha knockout mice. Endocrinology 1 41:2982-2994, 2000.
 
4) Forster C, Makela S, Warri A, et al:Involvement of estrogen receptor beta Interminai differentiation of mammary gland epithelium. Proc Natl Acad Sci U S A 99:15578-15583, 2002.
PubMed
5) Poola 1, Speirs V:Expression of alternatively spliced estrogen receptor alpha mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol 78:459-469, 2001.
 
6) Ogawa S, Inoue S, Watanabe T, et al:Molecular cloning and characterization of human estrogen receptor betacx:apotential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505-3512, 1998.
 
7) Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al:Estrogen receptor beta (ER beta) level but not its ER beta cx variant heips to predict tamoxifen resistance in breast cancer. Clin Cancer Res 10:5769-5776, 2004.
 
8) Smith CL, O'Malley BW:Coregulator function:a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71, 2004.
PubMed
9) Kushner PJ, Agard DA, Greene GL, et al:Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74:311-317, 2000.
 
10) Frasor J, Danes JM, Komm B, et al:Profiling of estrogen up-and down-regulated gene expression in human breast cancer cells; insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 1 44:4562-4574, 2003.
 
11) Urano T, Saito T, Tsukui T, et al:Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417:871-875, 2002.
PubMed
12) Buteau-Lozano H, Ancelin M, Lardeux B, et al:Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells; acomplex interplay between estrogen receptors alpha and beta. Cancer Res 62:4977-4984, 2002.
 
13) Elkin M, Cohen I, Zcharia E, et al:Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res 63:8821-8826, 2003.
PubMed
14) Elkin M, Orgel A, Kleinman HK:An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor l. JNatl Cancer Inst 96:875-878, 2004.
 
15) Fujita N, Jaye DL, Kajita M, et al:MTA 3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113:207-219, 2003.
 
16) Muller A, Homey B, Soto H, et al:Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56, 2001.
PubMed
17) Hall JM, Korach KS:Stromal cell-derived factor I, anovel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 17:792-803, 2003.
 
18) Kurebayashi J:Resistance to endocrine therapy in breast cancer. Cancer Chemother Pharmacol 56 (Suppl 7):39-46, 2005.
 
19) Coombes RC, Hall E, Gibson LJ, et al:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
PubMed
P.228 掲載の参考文献
1) Miller WR, Hawkins RA:Forrest APM Significance of aromatase actlvity In human breast cancer. Cancer Res 42:3365-3368, 1982.
 
2) Perel E, Wilkins D:Killinger DW The conversion of androstenedione to estrone, estradiol and testosterone In breast tissue. J Steroid Biochem 13:89-94, 1980.
 
3) Sasano H, Nagura H, Harada N, et al:Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathology 25:530-535, 1994.
PubMed
4) Sasano H, Kimura M, Shizawa S, et al:Aromatase and steroid receptors in gynecomastia and male breast carcinoma; an immunohistochemical study. Journal of Clinical Endocrinology & Metabolism 81:3063-3067, 1996.
PubMed
5) Sasano H, Frost AR, Saitoh R, et al:Aromatase and 17 beta-hydroxysteroid dehydrogenase type I in human breast carcinoma. Journal of Clinical Endocrinology & Metabolism 81:4042-4046, 1996.
PubMed
6) Sasano H, Harada N:Intratumoral aromatase in human breast, endometrial, and ovarian malig. nancies. Endocrine Review l 9:593-607, 1998.
 
7) Bulun SE, Price TM, Aitkerl J, et al:A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P 450 transcripts using competitive poiymerase chain reaction after reverse transcription. J Clin Endocrinol Metab 77:1622-1528, 1993.
 
8) Bulun SE, Mahendroo MS, Price T, et al:AIink between breast cancer and local estrogen biosynth. esis suggested by quantification of breast adipose tissue aromatase cytochrome P 450 transcripts by competitive PCR. J Clin Endocrinol Metab 77:1622-1628, 1993.
 
P.236 掲載の参考文献
1) 長村義之, 梅村 忍, 伊藤仁:モノクローナル抗体Trastuzumab (Herceptin) をめぐって EGFR family; proto oncogene, HER function, HER 2 (c-erbB-2) protein. Pharma Medica 18 (5):115-122, 2000.
 
2) Rubin l, Yarden Y:The basic biology of HER 2. Annals of Oncology 12 Supplement 1:3-8, 2001.
 
3) Adjei AA, Hidalgo M:Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. J Clin Oncol 23:5386-5403, 2005.
PubMed
4) Oda K, Matsuoka Y, Funahashi A, et al:A comprehensive pathway map of epidermal growth factor receptor signaling. Molecular Systems Biology 2005 doi:10. 1038/mbs 4100014.
 
5) 芹澤昭彦, 伊藤 仁, 宮嶋葉子, ほか:乳癌におけるCISH法を用いたHER 2遺伝子検出の組織標本, 細胞標本への応用. 日臨細胞誌43 (1):184, 2004.
 

VI. 手術療法

P.245 掲載の参考文献
1) Halsted WS:The results of operatlons for the cure of cancer of the breast performed at the John Hopkins Hospital from June, 1889 to January, 1894. Ann Surg 20:497-555, 1894.
 
2) Patey DH, Dyson WH:The prognosis of carcinoma of the breast in relation to the type of operarion performed. Br J Cancer 2:7-13, 1948.
 
3) Auchincloss H:Significance of location and number of axillary metastases in carcinoma of the breast; A justifications for a conservative operation. Ann Surg 158:37-46, 1963.
 
4) The Japanese Breast Cancer Society, President:Hiroshi Sono, Academic Committee Chairperson:Mamoru Fukuda; Results of Questionnaires concerning Breast Cancer Surgery in Japan 1980-2003. Breast Cancer 12:1-2, 2005.
 
5) 日本乳癌学会 (編):臨床・病理 乳癌取扱い規約. 第15版, 金原出版, 東京, 2004.
 
6) 日本乳癌学会 (編):科学的根拠に基づく乳癌診療ガイドライン, 2 外科療法. 2005年版, 金原 出版, 東京, 2005.
 
7) 高橋かおる:手術療法. ナースのための最新乳癌テキスト, 第1版, 内田 賢・秋山 太 (編), pp 76-92, 真興交易医書出版部, 東京, 2003.
 
8) 高橋かおる, 吉本賢隆, 霞富士雄:一般・消化器外科における局所解剖; 乳腺, 胸筋, 内胸動脈領域.手術53:1121-1127, 1999.
 
9) Kodama H:Modification of muscle-preserving radical mastectomy. Cancer 44:1517-1522, 1979.
PubMed
P.253 掲載の参考文献
1) The Japanese Breast Cancer Society:Results of questionnaires concerning breast cancer surgery in Japan 1980-2003. Breast Cancer 12:1, 2005.
 
2) Veronesi U, Cascinelli N, Mariani L, et al:Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 347:1227-1232, 2002.
PubMed
3) Fisher B, Anderson S, Bryant J, et al:Twenty-yearfoolow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233-1241, 2002.
PubMed
4) Arriagada R, Le MG, Guinebreitiere JM, et al:Local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 14:1617-1622, 2003.
 
5) Jacobson JA, Danforth DN, Cowan KH, et al:Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 332:907-911, 1995.
 
6) van Dongen JA, Voogd AC, Fentiman IS, et al:Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy:European organization for research and treatment of cancer 10801 trial. J Natl Cancer Inst 92:1143-1150, 2000.
 
7) Blichert-Toft M, Rose C, Andersen JA, et al:Danish randomized trial comparing breast conservation therapy with mastectomy:Six years of life-table analysis, Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 11:19-25, 1992.
 
8) 稲治英生, 菰池佳史, 柄川千代美, ほか:乳房温存療法後の乳房内再発とその治療. 乳癌の臨 19:533-538, 2004.
Medical*Online
9) Schnitt SJ, Connolly JL, Khettry U, et al:Pathologic findings on re-excision of the primary site in breast cncer patients considered for treatment by primary radiation therapy. Cancer 59:675-681, 1987.
 
10) Schnitt SJ, Abner A, Gelman R, et al:The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancertreated with breast-conserving surgery and radiation therapy. Cancer 74:1746-1751, 1994.
 
11) Leopold KA, Recht A, Schnitt SJ, et al:Results of conservative surgery and radiation in the treatment of synchronous cancers of one breast. Int J Radiat Oncol Biol Phys 16:11-16, 1989.
PubMed
12) Kurtz JM, Jaczuemier J, Amalric R, et al:Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 212:38-44, 1990.
 
13) Wilson LD, Beinfield M, McKhann CF, et al:Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer 72:137-142, 1993.
PubMed
14) Cho LC, Senzer N, Peters GN:Conservative surgery and radiation therapy for macroscopically multiple ipsilateral invasive breast cancers. Am J Surg 183:650-654, 2002.
PubMed
15) HartsellWF, Recine DC, Griem KL, et al:Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy? Int J Radiat Oncol Biol Phys 30:49-53, 1994.
 
16) Kaplan J, Giron G, Tartter Pl, et al:Breast conservation in patients with multiple ipsilateral synchronous cancers. J Am Coll Surg 197:726-729, 2003.
 
17) Okumura S, Mitsumori M, Tamauchi C, et al:Feasibility of breast-conserving therapy for macros-copically multiple ipsilateral breast cancer. Int J Radiat Oncol Biol Phys 59:146-151, 2004.
 
18) Singletary SE:Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 184:383-393, 2002.
PubMed
19) Recht A, Silen W, Schnitt SJ, et al:Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys 15:255-261, 1988.
PubMed
20) Voogd AC, van Tienhoven G, Peterse HL, et al:Local recurrence after breast conservation therapy for early stage breast carcinoma:Detection, treatment, and outcome in 266 patients. Cancer 85:437-446, 1999.
PubMed
21) Smith TE, Lee D, Turner BC, et ai:True recurrence vs. new primary ipsilateral breast tumor relapse:an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J RAdiat Oncol Biol Phys 48:128 i-1289, 2000.
 
22) Huang E, Buchholtz TA, Meric F, et al:Classifying local disease recurrences after breast conservation therapy based on location and histology:new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 95:2059-2067, 2002.
 
23) Krauss DJ, Kestin LL, Mitchell C, et al:Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications. Int J Radiat Oncol Biol Phys 60:731-740, 2004.
PubMed
24) Komoike Y, Akiyama F, lino Y, et al:Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer 12:104-111, 2005.
 
25) Santiago RJ, Wu L, Harris E, et al:Fifteen-year results of breast-conserving surgery and definitive irradiation for stage I and II breast carcinoma; The University of Pennsy Ivania experience. Int J Radiat Oncol Biol Phys 58:223-240, 2004.
 
26) Kuerer HM, Arthur DW, Haffty BG:Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence; The potential role of partial breast irradiation. Cancer 100:2269-2280, 2004.
PubMed
27) Fisher B, Anderson S, Fisher ER, et al:Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 338:327-331, 1991.
PubMed
28) Vicini FA, Kestin L, Huang R, et al:Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 97:910-919, 2003.
PubMed
P.261 掲載の参考文献
1) Nieweg OE, Tanis PJ, Kroon BBR, et al:The definition of a sentinel node. Ann Surg Oncol 8:538-541, 2001.
 
2) Morrow M:Management of the axillary nodes. Breast Cancer 6:1-12, 1999.
 
3) Krag DN, Weaver DL, Alex JC, et al:Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2:335-340, 1993.
PubMed
4) Giuliano AE, Kirgan DM, Guenther JM, et al:Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391-401, 1994.
PubMed
5) Cox CE:Lymphatic mapping in breast cancer:Combination technique. Ann Surg Oncol 8:67-70, 2001.
 
6) 武井寛幸, 末益公人:第2章, 診断, センチネルリンパ節生検 (2); 正診率乳腺疾患; state of arts, 伊藤良則, 戸井雅和 (編), pp 141-143, 医歯薬出版, 東京, 2004.
 
7) Schwartz GF, Giuliano AE, Veronesi U, the Consensus Conference Committee:Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Phiadelphia, Pennsylvania. Cancer 94:2542-2551, 2002.
 
8) 武井寛幸, 末益公人, 黒住昌史:乳がんにおけるセンチネルリンパ節生検 (腋窩非郭清) の予後に及ぼす影響. 血液・腫瘍科48:554-560, 2004.
 
P.267 掲載の参考文献
1) 高橋かおる, 西村誠一郎, 多田敬一郎,ほか:乳房温存治療の適応と限界. 癌と化学療法29:1125-1131, 2002.
 
2) 日本乳癌学会学術委員会, ガイドライン作成小委員会:乳房温存療法ガイドライン (1999). 乳癌の臨床15:147-156, 2000.
 
3) 厚生労働科学研究費 がん臨床研究事業 標準的な乳房温存療法の実地要項の研究班:IV病理 検索乳房温存療法のガイドライン. pp 21-25, 2005.
 
4) 秋山 太, 坂元吾偉, 霞富士雄:乳房温存手術断端陽性の治療方針. 乳癌の臨床14:296-300, 1999.
 
P.271 掲載の参考文献
1) 日馬幹弘, 中山俊, 海瀬博史, ほか:probe lumpectomyとday y surgery. 臨床外科 57:313-319, 2002.
 
2) 河本敦夫, ほか:フルデジタル超音波装置を用いた乳腺超音波検査. 映像情報 32:511-516, 2000.
Medical*Online
3) 日馬幹弘, ほか:膨隆局所麻酔 (tumescent local anesthesia:TLA) 法による乳腺手術. 手術 2005 (投稿中).
 
4) 日馬幹弘, ほか:Day Surgery; 手術のコツとピットフォール1 乳癌 (センチネルリンパ節生検を伴う). 手術56:427-433, 2002.
 
5) 日馬幹弘:乳癌に帰り手術のコツと留意点. 乳癌治療のコツと落とし穴, 霞 富士雄 (編), pp 228-229, 中山書店, 東京, 2004.
 
6) 日馬幹弘:乳癌の日帰り手術手技とその要点. 乳癌診療二頁の秘訣, 光山昌珠 (編), pp 190-191, 金原出版, 東京, 2004.
 
P.278 掲載の参考文献
1) 尾浦正二,櫻井武雄,吉村吾郎,ほか:血性乳汁分泌を伴う乳癌に対する乳頭温存の可能性. 手術49:1413-1417, 1995.
 
2) 尾浦正二,櫻井武雄,吉村吾郎,ほか:整容効果からみた乳頭温存手術の適応. 日外科系連会誌20:109-113, 1995.
 
3) 尾浦正二,櫻井武雄,吉村吾郎,ほか:乳頭下乳腺組織切離におけるthick flapの有用性. 日癌治療会誌30:1824-1834, 1995.
 
4) 尾浦正二,櫻井武雄,吉村吾郎,ほか:乳頭温存術式 (Glt+Ax) 施行例で乳頭側切除断端に乳管内進展巣が見られた症例の臨床的検討. 日臨外医会誌55:1656-1659, 1994.
 
5) 尾浦正二, 平井一成, 吉増達也, ほか:Cool-tip RFニードルによる乳癌ラジオ波熱凝固療法. Progress In Medicine 24:2751-2755, 2004.
Medical*Online
P.289 掲載の参考文献
1) 日本乳癌学会学術委員会 (編):乳房温存療法ガイドライン (1999). 教育広報社, 東京, 1999.
 
2) 山川達郎, 酒井 滋, 石川泰郎, ほか:腹腔鏡的胆嚢摘出術の手技. 臨床外科45:1255-1259, 1990.
 
3) 福間英祐:内視鏡下乳腺全摘術. 手術53:153-159, 1999.
 
4) 山形基夫, ほか:乳癌に対する内視鏡下乳房温存術. 日本内視鏡外科学会誌4(1):41-45, 2000.
 
5) 石黒清介, ほか:鏡視補助下乳腺部分切除術と郭清術. 外科治療83:673-677, 2000.
 
6) 福間英祐:"内視鏡下手術の再評価"乳腺手術. 外科治療83(4):435-442, 2000.
 
7) 福間英祐, 比嘉国基:内視鏡下前哨リンパ節生検 日鏡外会誌6(1):74-80, 2001.
 
8) 福間英祐, 宇井義典, 館花明彦, ほか:乳癌に対する鏡視下乳腺全摘術と再建術. 帝京医学会誌21(6):497-503, 1999.
 
9) Hultman CS, Daiza S:Skin-sparing mastectomy flap complications after breast reconstruction; review of incidence, management, and outcome. Ann Plast Surg 50(3):249-255:discussion 255, 2003.
PubMed
10) Vandeweyer E:Peri-areolar skin-sparing mastectomy and immediate tram flap reconstruction. Acta Chir Belg 103(2):219-224, 2003.
PubMed
11) 佐貫潤一, 福間英祐, ほか:乳房温存手術後の整容性向上のための工夫. 乳癌の臨床:486-487, 2003.
Medical*Online
12) 児玉 宏:胸筋温存乳癌根治術. 金芳堂, 京都, 1988.
 
13) Price Cl, Eaves FF, Nahai F:Endoscopic tansaxillary subpectral breast augmentation. Plastic Reconstructive Surgery 94:612-619, 1994.
 
14) Johnson GW, Christ JE:The endoscopic breast augmentation; the transumblical insertion of saline-filled breast implants. Plast Reconstr Surg 92:801-808, 1992.
 
15) Dunn MD, Portis AJ, Shalhav AL, et al:Laparoscopic versus open radical nephrectomy; A 9-year experience. J Urol 164:1153-1159, 2000.
PubMed
16) Fliedlander LD, Sundin J, Bakshandeh N:Endoscopy mastectomy and breast reconstruction:Endoscopic breast surgery. Aesth Plat Surg 19:27-29, 1995.
 
17) Salvat J, Knopf JF, Ayoubi JM:Endoscopic exploration and lymph node sampling of the axilla; Preliminary findings of a randomized pilot study comparing clinical and anatomo-pathologic results of endoscopic axillary lymph node sampling with traditional surgical treatment. Eur J Obstet Gynecol Reprod Biol 70(2):165-173, 1996.
PubMed
18) Gianfelice D, Khiat A, Amara M:MR imaging-guided focused US ablation of breast cancer; histopathoiogic assessment of effectiveness-initial experience. Radiology 227(3):849-855, 2003.
PubMed
19) Pfleiderer SO, Freesmeyer MG, Marx C, et al:Cryotherapy of breast cancer under ultrasound guidance:initial results and limitations. Eur Radiol 12(12):3009-3014, 2002.
PubMed
P.306 掲載の参考文献
1) 肺塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン作成委員会:肺塞栓症/深部静脈血栓症 (静脈血栓塞栓症) 予防ガイドライン. メディカルフロントインターナショナルリミテッド, 東京, 2004.
 
2) 炭山嘉伸:外科感染症;一般消化器外科領域. 抗菌薬使用の手引き, 第1版, 日本感染症学会, 日本化学療法学会 (編), 協和企画, 東京, 2001.
 
3) Mangram AJ, Horan TC, Pearson ML, et al:Guideline for prevention of surgical site infection, 1999; Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 20:250-278, 1999.
PubMed
4) 池田 正:術後の疼痛防止. 乳腺外科の要点と盲点, 第1版, 霞 富士雄 (編), pp 234-235, 文光堂, 東京, 1998.
 
5) Dow KH, Kalinowski BH:Nursing Care in Patient Management and Quality of Life. Diseases of the Breast, 3rd ed, Harris JR, Lippman ME, Monica M, et al (eds), pp 1387-1404, Lippincott Williams & Wilkins A Wolters Kluwev Company, Philadelphia, 2004.
 
P.314 掲載の参考文献
1) Noguchi M:Radiofrequency ablation treatment for breast cancer to meet the next challenge:How to treat primary breast tumor without surgery. Breast Cancer 10:1-3, 2003.
PubMed
2) Noguchi M:Minimally invasive surgery for small breast cancer. J Surg Oncol 84:94-101, 2003.
PubMed
3) Singletary SE:Feasibility of radiofrequency ablation for primary breast cancer. Breast Cancer 10:4-9, 2003.
 
4) Jeffrey SS, Birdwell RL, Ikeda DM, et al:Radiofrequency ablation of breast cancer. Arch Surg 134:1064-1068, 1999.
PubMed
5) Izzo F, Thomas R, Delrio P, et al:Radiofrequency ablation in patients with primary breast carcinoma; A pilot study in 26 patients. Cancer 92:2036-2044, 2001.
PubMed
6) Burak Jr. WE, Agnese DM, Povoski SP, et al:Radiofrequency ablation of invasive breast cancer followed by delayed surgical excision. Cancer 98:1369-1376, 2003.
PubMed
7) Mirza AN, Fornage BD, Sneige N, et al:Radiofrequency ablation of early-stage invasive breast tumors; results of a multi-center study. Breast Cancer Res Treat 96 (s 19):s116, 2002.
 
8) Hayashi AH, Silver SF, van der Westhuizen NG, et al:Treatment of invasive breast carcinoma with ultrasound-guided radiofrequency ablation. Am J Surg 185:429-435, 2003.
PubMed
9) Elliott R, Rice PB, Sutts JA, et al:Radiofrequency ablation of a stereotactically localized nonpalpable breast carcinoma. Am Surg 68:1-5, 2002.
 
10) 野口昌邦, 江嵐充治, 月岡雄治, ほか:乳癌に対する高周波熱凝固療法. 外科67:197-204, 2005.
 
11) Fornage BD, Sneige N, Ross MI, et al:Small (<or=2-cm) breast cancer treated with US-guided radiofrequency ablation; feasibility study. Radiology 231:215-224, 2004.
 
12) Hall-Craggs MA:Interventinal MRI of the breast; minimally invasive therapy, Eur Radiol 10:59-62, 2000.
 
13) 山道 昇:Stage 1乳癌および良性乳腺疾患に対するRF ablation療法. 乳癌低侵襲療法第1回 ミニシンポジウム, 第42回北陸乳癌懇話会, 金沢, 2004.
 
14) 位籐俊一, 水野 均, 水島恒和, ほか:乳癌に対するラジオ波焼却療法の意義. 乳癌低侵襲療法第1回ミニシンポジウム, 第42回北陸乳癌懇話会, 金沢, 2004.
 
15) 尾浦正二:ラジオ波熱凝固療法の試み. 乳癌低侵襲療法第1回ミニシンポジウム, 第42回北陸乳癌懇話会, 金沢, 2004.
 

VII. 薬物療法

P.321 掲載の参考文献
1) Schwartz GF, Hortobagyi GN, the Consensus Conference Committee:Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. Cancer 100:2512-2532, 2004.
 
2) Kaufmann M, von Minckwitz G, Smith R, et al:International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer:review and recommendations. J Clin Oncol 21:2600-2608, 2003.
 
3) Wolmark N, Wang J Mamounas E, et al:Preoperative chemotherapy in patients with operable breast cancer:nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001.
PubMed
4) van der Hage JA, van de Velde CJH, Julien JP, et al:Preoperative chemotherapy in primary operable breast cancer:results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237, 2001.
 
5) Estevez LG, Gradishar WJ:Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 10:3249-3261, 2004.
PubMed
6) Smith IC, Heys SD, Hutcheon AW, et al:Neoadjuvant chemotherapy in breast cancer; significantly enhanced response with docetaxel J Clin Oncol 20:1456-1466, 2002.
PubMed
7) Bear HD, Anderson S, Brown A, et al:The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide:preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174, 2003.
PubMed
8) von Minckwitz G, Raab G, Caputo A, et al:Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer; the GEPARDUO Study of the German Breast Group. J Clin Oncol 23:2676-2685, 2005.
 
9) Evans TR, Yellowlees A, Foster E, et al:Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer:an Anglo-Celtic Cooperative Oncology Group Study. J Clin Oncol 23:2988-2995, 2005.
 
10) 日本乳癌学会 (編):乳癌診療ガイドライン(1)薬物療法. pp 46-54, 金原出版, 東京, 2004.
 
11) Petit T, Wilt M, Velten M, et al:Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40:205-211, 2004.
PubMed
12) Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al:Invasive lobular carcinoma classic type; response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48, 2005.
PubMed
13) Iwao-Koizumi K, Matoba R, Ueno N, et al:Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431, 2005.
PubMed
14) Dunnwald LK, Gralow JR, Ellis GK, et al:Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 103:680-688, 2005.
PubMed
15) Veronesi U, Bonadonna G, Zurrida S, et al:Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222:612-618, 1995.
PubMed
16) Touboul E, Lefranc J-P, Blondon J, et al:Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 42:219-229, 1997.
PubMed
17) Bonadonna G, Valagussa P, Brambilla C, et al:Primary chemotherapy in operable breast cancer; eight-year experience at the Milan Cancer Institute. J Clin Oncol 16:93-100, 1998.
PubMed
18) Danforth DN, Zujewski J, O:Shaughnessy J, et al:Selection of local therapy after neoadjuvant chemotherapy in patients with stage 111A, B breast cancer. Ann Surg Oncol 5:150-158, 1998.
 
19) Mauriac L, MacGrogan G, Avril A, et al:Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm; a unicentre randomized trial with a 124-month median follow-up. Ann Oncol 10:47-52, 1999.
 
20) Kuerer HM, Newman LA, Smith TL, et al:Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469, 1999.
PubMed
21) McIntosh SA, Ogston KN, Payne S, et al:Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 185:525-531, 2003.
PubMed
22) Rouzier R, Mathieu M-C, Sideris L, et al:Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer 101:918-925, 2004.
PubMed
23) Chen AM, Meric-Bernstam F, Hunt KK, et al:Breast conservation after neoadjuvant chemotherapy; the M. D. Anderson Cancer Center experience. J Clin Oncol 22:2303-2312, 2004.
 
24) Shen J, Valero V, Buchholz TA, et al:Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 11:854-860, 2004.
PubMed
25) Inaji H, Komoike Y, Motomura K, et al:Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer. Breast Cancer 9:20-25, 2002.
PubMed
26) 稲治英生, 柄川千代美, 菰池佳史, ほか:術前化学療法後の乳房温存療法. Breast Cancer Today 21:2-7, 2005.
 
27) Chen AM, Meric-Bernstam F, Hunt KK, et al:Breast conservation after neoadjuvant chemotherapy; a prognostic index for clinical decision-making. Cancer 103:689-695, 2005.
PubMed
28) Kim S-J, Kim S-k, Lee ES, et al:Predictive value of [18F] FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15:1352-1357, 2004.
PubMed
29) Thomas E, Holmes FA, Smith TL, et al:The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer long-term results from a prospective randomized trial. J Clin Oncol 22:2294-2302, 2004.
 
30) Pockaj BA, Gray RJ:Surgical management of locally advanced breast cancer. ASCO Educational Book 85-91, 2004.
 
31) Charfare H, Limongelli S, Purushotham AD:Neoadjuvant chemotherapy in breast cancer. Br J Surg 92:14-23, 2005.
PubMed
32) Mamounas EP, Brown A, Anderson S, et al:Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer:results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23:2694-2702, 2005.
PubMed
33) Sabel MS, Schott AF, Kleer CG, et al:Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 186:102-105, 2003.
PubMed
34) Schrenk P, Hochreiner G, Fridrik M, et al:Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J 9:282-287, 2003.
PubMed
35) Huober J, Krainick-Strobel U, Kurek R, et al:Neoadjuvant endocrine therapy in primary breast cancer. Clin Breast Cancer 5:341-347, 2004.
PubMed
36) Dixon JM, Anderson TJ, Miller WR:Neoadjuvant endocrine therapy of breast cancer; a surgical perspective. Eur J Cancer 38:2214-2221, 2002.
PubMed
37) Dowsett M, Ebbs SR, Dixon JM, et al:Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination; influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23:2477-2492, 2005.
 
38) Buzdar AU, Ibrahim NK, Francis D, et al:Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685, 2005.
PubMed
39) Mohsin SK, Weiss HL, Gutierrez MC, et al:Neoadjuvant trastuzumab induces apoptosis in primarybreast cancers. J Clin Oncol 23:2460-2468, 2005.
 
P.333 掲載の参考文献
1) Goldhirsch A, Wood WC, Gelber RD, et al:Meeting highlights:updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21(17):3357, 2003.
PubMed
2) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights; International Consensus Panel on the Treatment of Primary Breast Cancer, Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19(18):3817-3827, 2001.
 
3) Allred DC, Harvey JM, Berardo M, et al:Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol II (2):155-, 1998.
 
4) Ellis MJ, Coop A, Singh B, et al:Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:evidence from a phase III randomized trial. J Clin Oncol 19(18):3808-3816, 2001.
 
5) Coombes RC, Hall E, Gibson LJ, et al:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(II):1081-1092, 2004.
 
6) Howell A, Cuzick J, Baum M, et al:ATAC Trialists:Group:Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years:adjuvant treatment for breast cancer. Lancet 365 (9453):60-62, 2005.
PubMed
7) Baum M:Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control II:217-221, 2004.
 
8) Henderson IC, Berry DA, Demetri GD, et al:Improved outcome from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003.
PubMed
9) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights; international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16(10):1569-1583, 2005.
PubMed
P.340 掲載の参考文献
1) Fisher B:The contribution of recent NSABP clinical trial of primary breast cancer therapy to an understanding of tumor biology, an overview of findings. Cancer 46:1009-1025, 1980.
 
2) 西條長宏:化学療法の効く癌・効かない癌. 代謝20:907-915, 1983.
 
3) 田部井敏夫, ほか:Intensive chemotherapyとPalliative chemotherapyの選択; 乳癌. 癌治療と宿王16:355-360, 1994.
 
4) Glordano SH, et al:Is breast cancer survival improvlng? Cancer 100:44-52, 2004.
 
5) Hortobagyi GN:Treatment of breast cancer. New Engl J Med 339:974-984, 1998.
PubMed
6) The Australian and New Zealand Breast Cancer Trials Group:A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or combination. J Clin Oncol 4:186-193, 1986.
 
7) Hortobagyi GN:Options for treatment of metastatic breast cancer. ASCO 12:515-521, 1999.
 
8) Bonadonna G, et al:Adjuvant cyclophosphamide methotrexate and fluorouracil in node-positive breast cancer:the results of 20 years of follow-up. New Engl J Med 332:901-906, 1995.
PubMed
9) Sledge GW, et al:Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A+T) as first line therapy for metastatic breast cancer (MBC):an intergroup trial. Proc AM Soc Clin Oncol 16:1a (abstract 2), 1997.
 
10) Adachi I, et al:phase II study of RP 56976 (docetaxel) in patients with advanced or recurrent breastcancer. Br J cancer 73:210-216, 1996.
PubMed
11) Ito Y, et al:Phase Ii study of paclitaxel (BMS 181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. Invest New Drugs 16:183-190, 1998.
PubMed
12)小川一誠:乳癌化学療法の現状と未来; 進行乳癌に対する化学療法. 乳癌の臨床8:205-212, 1993.
 
P.347 掲載の参考文献
1) 伊藤良則. レジデントハンドブック乳癌薬物療法. 第1版, 真興交易医書出版部, 東京, 2004.
 
2) 伊藤良則, 戸井雅和 (編):乳腺疾患state of arts. 医歯薬出版, 東京, 2004.
 
3) 伊藤良則. 心配しないでいいですよ再発・転移乳がん. 畠 清彦 (編), 真興交易医書出版部, 東京, 2003.
 
4) 日本乳癌学会 (編):科学的根拠に基づく乳癌診療ガイドライン薬物療法金原出版, 東京, 2004.
 
P.356 掲載の参考文献
1) 岩瀬弘敬, 山下啓子, 遠山竜也, ほか:有効な補助療法 乳癌のホルモン療法. 臨床と研究 79(3):419-423, 2002.
 
2) Miller WR:Aromatase and its inhibitors; new biology and clinical perspectives. Endocr Relat Cancer 6:127-130, 1999.
PubMed
3) Vogel CL, Schoenfelder J, Shemano I, et al:Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 13:1123-1128, 1995.
PubMed
4) 岩瀬弘敬:ホルモンレセプター (ER, PgR) の臨床病理学的意義 (測定と評価方法). 乳癌の抗アロマターゼ療法; 新たなる展開, pp 35-46, 医科学出版社, 東京, 2003.
 
5) Harvey JM, Clark GM, Osborne K, et al:Estrogen receptor Status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481, 1999.
 
6) Mohsin SK, Weiss H, Havighurst T, et al:Progesterone receptor by immunohistochemistriy and clinical outcome in breast cancer:a validation study. Mod Pathol 17:1545-1554, 2004.
PubMed
7) Allred DC, Harvey JM, Berardo M, et al:Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol II:155-168, 1998.
 
8) Ellis MJ, Coop A, Singh B, et al:Letrozole is more effective neoadjubant endocrine therapy than tamoxifen for erbB-land/or erbB-2-positive, estrogen receptor-positive privary breast cancer; evidence from a phase III randomize trial. J Clin Oncol 19:3808-3816, 2001.
 
9) Taylor CW, Green S, Dalton WS, et al:Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer; an intergroup study. J Clin Oncol 16:994-999, 1998.
PubMed
10) Klijin JGM, Blamey RW, Baccardo F, et al:Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer; a meta-analysis of four randomized trials. J Clin Oncol 19:343-353, 2001.
 
11) Forward DL, Cheung KL, Jackson L, et al:Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590-594, 2004.
 
12) Mouridsen H, Gershanovich M, Sun Y, et al:Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer; results of a phase III study of the Internationa Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001.
 
13) Paridaens R, Therasse P, Dirix L, et al:First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)-A randomized phase III trial of the EORTC Breast Group. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting ed) 22(14S) (July 15 Suppl):515, 2004.
 
14) Nabholtz JM, Buzdar A, Pollak M, et al:Anastrozole is superiot to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3767, 2000.
 
15) Bonneterre J, Thurlimann B, Robertson JFR, et al:Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women; results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol 18:3748-3757, 2000.
PubMed
16) Bonneterre J, Buzdar A, Nabholtz JM, et al:Anastrozole is superior to Tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma; Results of two randomized trials designed for combined analysis. Cancer 92:2247-2258, 2001.
PubMed
17) Nabholtz JM, Bonneterre J, Buzdar A, et al:Anastrozole (ArimidexTM) versus Tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women ; survival analysis and updated safety results. Eur J Cancer 39:1684-1689, 2003.
PubMed
18) Mouridsen H, Gershanovich M, Sun Y, et al:Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women; analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncology 21:2101-2109, 2003.
 
19) Buzdar A, Jonat W, Howell A, et al:Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advancer breast carcinoma. Cancer 83:1142-1152, 1998.
 
20) Dombernowsky P, Smith I, Falkson, G, et al:Letrozole, a new oral aromatase inhibitor for advanced breast cancer; double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998.
PubMed
21) Buzdar A, Douma J, Davidson N, et al:Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 19:3357-3366, 2001.
 
22) Kaufmann M, Bajetta E, Diric LY, et al:Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:results of a phase III randomized double-blind trial. J Clin Oncol 18:1399-1411, 2000.
 
23) Rose C, Vtoraya O, Pluzanska A, et al:An open randomized trial of second-line endocrine therapy in advanced breast cancer; comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318-2327, 2003.
PubMed
24) Johnston SRD:Endocrine manipulation in advanced breast cancer; recent advances with SERM therapies. Clin Cancer Res 7 (Suppl):4376s-4387s, 2001.
 
25) Lonning PE, Bajetta E, Murray R, et al:Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors:a phase II trial. J Clin Oncol 18:2234-2244, 2000.
PubMed
26) Bertelli G, Garrone O, Melano M, on behalf of the MIG 8 trial group:Sequential use of aromatase inactivators and inhibitors in advanced breast cancer. Annual Meeting Proceedings of American Society of Clinical Oncology:#238, 2002.
 
27) Thurlimann B, Robertson JFR, Nabholtz JM, et al:Efficacy of tamoxifen following anastrozole ("Arimidex") compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 39:2310-2317, 2003.
PubMed
28) van Veelen H, Willemese PH, Tjabbes T, et al:Oral high-dose medroxyprogesterone acetate versus tamoxifen:A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58:7-13, 1986.
 
P.365 掲載の参考文献
1) Hiraga T, Tanaka S, Ikegame M, et al:Morphorogy of bone metastasis. Eur J Cancer 34:230-239, 1998.
 
2) Kitazawa S, Fukase M, Kitazawa R, et al:Immunohistologic evaluation of parathyroid hormone-related protein in human lung cancer and normal tissue with newly developed monoclonal antibody. Cancer 15:984-989, 1991.
 
3) Powell GL, Southby J, Danks JA, et al:Localization of parathyroid hormone-related protein in breast cancer metastses; Increased incidence in bone compared with other sites. Cancer Res 51:3059-3061, 1991.
 
4) Kohno N, Kitazawa S, Sakoda Y, et al:Parathyroid hormone-related protein in breast cancer tissues:relationship between primary and metastatic sites. Breast Cancer 1:43-49, 1994.
 
5) Yin JJ, Chirgwin JM, Taylor SD, et al:Dominant negative blockade of the transforming growth factor β(TGFβ) type II receptor decreases breast cancer mediated osteolysis. J bone Minr Res II (Supl I)s 139, 1996.
 
6) 米田俊之:癌の骨への転移における副甲状腺ホルモン関連蛋白の役割. 腎と骨代謝12:23-29, 1999.
 
7) Fleisch H, Russell RG, Straumann F:Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 26; 212(65):901-903, 1966.
 
8) Sato M, Grasser W, Endo N, et al:Bisphosphonate action. Alendronate localization in rat bone and effect on osteoclast ultrastructure. J Clin Invest 88:2095-2105, 1994.
 
9) Rogers MJ, Gordon S, Benford HL, et al:Celllar and molecular mecanisum of action of bisphos-phonate. Cancer 88:2961-2978, 2000.
 
10) Benford HL, Frith JC, Auriola S, et al:Farneso and geranylgeraniol prevent activation of caspases by aminobisphosphonates; biochemical evidence for two distinct pharmacological classes of bisphos-phonate drug. Moi Pharmacol 56:131-140, 1999.
 
11) Hortobagyi GN, Theriault RL, Lipton A, et al:Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Onclo 16:2038-2044, 1998.
 
12) Theriault RL, Lipton A, Hortobagyi GN, et al:Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions; a randomized, placebo-controlled trial. J Clin Oncol 17:846-854, 1999.
 
13) Lipton A, Small E, Saad F, et al:The new bisphosphonate, Zometa (Zoledronic Acid), decreases skeletal complications in both osteolytic and osteoblastic lesions; a comparison to pamidronate. Cancer Invest 20(Supple):45-47, 2002.
 
14) Rosen LS, Gordon D, Kaminski M, et al:Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma; phase III, double-blinded, comparative trial Cancer J 7:377-387, 2001.
PubMed
15) Rosen LS, Gordon D, Tchekmedyian V, et al:Zoledoronic acid versus placebo in the treatment of skeletal metaqstases in patients with lung cancer and other solid tumors:A phase III, double blind, randomized trial-The Zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21:3150-3157, 2003.
 
16) Elomaa I, Blomqvist C, Porkka L, et al:Treatment of skeletal disease in breast cancer; a controlled clodoronate trial. Bone 8 (supple I):s53-56, 1987.
 
17) Blomqvist C, Elomaa I:Bisphosphonate therapy in metastatic breast cancer. Acta Oncol 35 (suppl 5):81-83, 1996.
 
18) Paterson AH, Powels TJ, Kanis JA, et al:Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11:59-65, 1993.
 
19) Kristensen B, Ejlertsen B, Groenvold M, et al:Oral clodoronate in breast cancer patients with bonemetastases:a randomized study. J Inter Med 246:67-74, 1999.
 
20) Hilner BE, Ingle JN, Berenson JR, et al:American society of clinical oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 18:1378-1319, 2000.
 
21) Coleman RE, Rosen LS, Gordon D, et al:Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compaired with pamidoronate (90 mg) in patients with breastcancer and bone metastasis. [abstract 355] at 25th Annual San Antonio Breast Cancer Symposium, pp 11-14, San Antonio, Texas, 2002.
 
22) Kohno N, Aogi K, Minami H, et al:Zoledoronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer; randomized, placebo-controlled trial. JCO 1-16:in print.
 
23) Hilner BE, Ingle JN] Chlebowski RT, et al:American society of clinical oncology 2003/10/18 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:1-16, 2003.
 
24) Sasaki A, Brendan F, Boyce B, et al:Bisphosphonate risedronate reduces metastatic human breastcancer burden in bone in nude mice. Cancer Res 55:3551-3557, 1995.
 
25) Diel IJ, Solomayer EF, Costa SD, et al:Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363, 1998.
PubMed
26) Saarto T, Blomqvist C, Virkkuen P, et al:Adjuvant clodrorlate treatment dose not reduce thefrequency of skeletal metastases in node-positive breast cancer patients:5-year results of a randomized control trial. J Clin Oncol 19:10-17, 2001.
PubMed
27) Powles T, Paterson S, Kanis JA, et al:Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 1:20(15):3219-3224, 2002.
PubMed
28) Kohno N, Kokufu I:Prevention of bone metastases from Breast cancer by adjuvant bisphosphonate therapy. Breast Cancer 10:33-37, 2003.
PubMed
P.372 掲載の参考文献
1) Tokuda Y, Watanabe T, Omuro Y, et al:Dose escalation and pharmacokinetic study of a humanised anti-HER 2 monoclonal antibody in patients with HER 2/neu-over-expressing metastatic breast cancer. Br J Cancer 81:1419-1425, 1999.
 
2) Cobleigh MA, Vogel CL, Tripathy D, et al:Multinational study of the efficacy and safety of humanized anti-HER 2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999.
PubMed
3) Vogel CL, Cobleigh MA, Tripathy D, et al:Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER 2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002.
PubMed
4) Slamon DJ, Leyland-Jones B, Shak S, et al:Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344:783-792, 2001.
 
5) Extra JM, Cognetti F, Chan S, et al:Randomised phase II trial (M 77001) of trastuzumab (Herceptin(R)) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER 2-positive metastatic breast cancer. Eur J Cancer I:S202(abstract 672), 2003.
 
6) Montemurro F, Valabrega G, Aglietta M:Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 5:81-96, 2004.
PubMed
7) Bangemann N, Kuhle A, Ebert A, et al:Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER 2-over expressing metastatic breast cancer (MBC). Ann Oncol II (Suppl 4):143, 2000.
 
8) Gelmon K, Mackey J, Verma S, et al:Efficacy and safety of Herceptin in women with Her 2-positive (HER 2+) metastatic breast cancer (MBC) who have progressed on a prior Herceptin-containing regimen. Breast Cancer Res Treat 76(suppl I):S113(abstract 440), 2002.
 
P.377 掲載の参考文献
1) 厚生省薬務局GCP研究会 (編):医師の為の治験ハンドブック. 改訂第5版, ミクス社, 東京, 2003.
 
2) Early Breast Camcer Trialists 'Collaborative Group:Polychemotherapy for early breast cancer; an overview of the randomized trials. Lancet 352:930-942, 1998.
 
3) Budman D, Berry D, Cirrincione C, et al:Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 90:1205-1211, 1994.
 
4) Henderson IC, Berry DA, Demetri D, et al:Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003.
 
5) Fisher B, Anderson S, Wickerham DL, et al:Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer; findings from National Surgical Adjuvent Breast and Bowel Project B-22. J Clin Oncol 15:1858-1869, 1997.
 
6) Fisher B, Anderson S, DeCillis, et al:Further evaluation of intensified and increased total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of the primary breast cancer:Findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 17:3374-3388, 1999.
 
7) Hillner BE, Ingle JN, Chlebowski RT, et al:American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonate and Bone health issue in women with breast cancer. J Clin Oncol 21:4042-4057, 2003.
 
8) Theriault RL, Lipton A, Hortobagyi GN, et al:Pamindronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions; A randomized, placebo-controlled trial. J Clin Oncol 17:846-854, 1999.
 
9) Coleman RE:Efficacy of zoledornic acid and pamindronate in breast cacner patients:a comparative analysis of romdomized phase III trials. Am J Clin Oncol 25:S25-31, 2002.
 
10) Rosen LS, Gordon D, Tchkmedyian S, et al:Zolodoronic acid versus placebo in the retment skeletal metastasis in patients with lung cancer and other solid tumors:a phase III, double-blind, randomized trial-the Zoledronic acid lung cancer and other tumor study goup. J Clin Oncol 15:3150-3157, 2003.
 
11) Cavalletti AM:Oral and intravenouse BNP 7787 protects against paclitaxel-mediated neurotoxicityin Winster rats. Proc Am Assoc Cancer Res 40, abstract #2632:398, 1999.
 
12) Sakata Y, Ohtsu A, Horikoshi N, et al:Late phase II study of novel oral fluoropyrimidine anticancer drug S-I in advanced gastric cancer patients. Eur J Cancer 34:1715-1720, 1998.
 
13) Saeki T, Takashima S, Sano M, et al:Aphase II study of S-I in patients with metastatic breastcancer-A Japanese trial by S-I cooperative study group, Breast Cancer Working Group. Breast Cancer II:194-202, 2004.
 
14) Sato N, Sato Y, Saeki T, et al:The cumulative dose of previouse treatment dose not relate to efficacy of S-I in patients with taxane resistant breast cancer. Proc San Antonio Breast Can Symp:San Antonio abstract #1078, 2004.
 
15) Hirata K, Horikoshi N, Aiba K, et al:Pharmacokinetic study of S-I, a novel oral fluorouracil anticancer drug. Clin Cancer Res 5:2002-2005, 1999.
 
16) 冨永 健, 野村雍夫, 安達 勇, ほか:KW-2307の進行・再発乳癌に対する後期第ll相試験. 癌と化学療法21:809-816, 1994.
 
17) 佐伯俊昭, 安達 勇, 荻田征美, ほか:進行・再発乳癌に対するVinorelubineを含む多剤併用療法. 癌と化学療法27:1180-1184, 2000.
 
18) Burstein HJ, Kuter I, Campas SM, et al:Clinical activity of trastuzumab and vinorelbine in women with HER 2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001.
 
19) Tominaga T, Adachi l, Sasaki Y, et al:Double-blind randomized trial comparing the non-steroidal aromatase inhibitors Ietrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol 14:62-70, 2003.
 
20) Goss PE, Ingle J, Martino S, et al:A rondomized trial of letrozole in postmenopausal women after five years of Tamoxifen Therapy for Early-Stage Breast Cancer. New Engl J Med 349:1-10, 2004.
 
21) Thurlimann B (BIG-98 Collaborative group):BIG 1-98:A prospective randomized double-blind double-dummy phase III study to evaluate Letrozol as adjuvant endocrine therapy for post-menopausal women with receptor-positive breast cancer. 9th, International conferernce, St. Gallenabstract # S 4, Swiss, 2005.
 
22) Burris HA, Taylar C, Jones S, Pandite L, et al:A phase I study of GW 572016 in patients with solid tumors. Proc Am Soc Clin Oncol:abstract #994, 2003.
 
23) Fong TAT, Shawver LK, Sun L, et al:SU-5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor that inhibits tyrosine kinase catalysis, tumor vascularrization, and growth of multiple tumor-types. Cancer Res 59:5412-5416, 1999.
 
24) Machida S, Saga Y, Takei Y, et al:Inhibition of peritoneal dissemination of ovarian cancer by tyrpsine kinase receptor inhibitor SU 6668 (TSU-68). J Cancer 114(2):224-229, 2005.
 
P.386 掲載の参考文献
1) Fisher B, Costantino JP:Tamoxifen for prevention of breast cancer; report of the national surgical adjuvant breast and bowel project P-I study. J Natl Cancer Inst 91:1891A-1892, 1999.
 
2) Cuzick J, Forbes J, Edwards R, et al:First results from the International Breast Cancer Intervention Study (IBIS-1):a randomised prevention trial Lancet 360:817-824, 2002.
PubMed
3) Veronesi U, Maisonneuve P, Costa A, et al:Prevention of breast cancer with tamoxifen; preliminary findings from the Italian randomised trial among hysterectomised women, Italian Tamoxifen Prevention Study. Lancet 352:93-97, 1998.
PubMed
4) Powles T, Eeles R, Ashley S, et al:Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998.
 
5) Cuzick J, Powles T, Veronesi U, et al:Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300, 2003.
PubMed
6) Cummings SR, Eckert S, Krueger KA, et al:The effect of raloxifene on risk of breast cancer in postmenopausal women; results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 81:2189-2197, 1999.
PubMed
7) Cauley JA, Norton L, Lippman ME, et al:Continued breast cancer risk reduction in postmenopausal women treated with raloxifene:4-year results from the MORE trial, Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134, 2001.
PubMed
8) Cummings SR, Duong T, Kenyon E, et al:Multiple Outcomes of Raloxifene Evaluation (MORE) Trial:Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220, 2002.
PubMed
9) Gail MH, Brinton LA, Byar DP, et al:Projecting individualized probabilities of developing breastcancer for white females who are being examined annually. J Natl Cancer Inst 81:1879-1886, 1989.
 
10) Anderson SJ, Ahnn S, Duff K:NSABP Breast Cancer Prevention Trial risk assessment program. version 2; NSABP Biostatistical Center Technical Report, August 14, 1992.
 
11) http://bcra.nci.nih.gov/brc/
PubMed
12) Gail MH, Costantino JP, Bryant J, et al:Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829-1846, 1999.
PubMed
13) Freedman AN, Graubard Bl, Rao SR, et al:Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 95:526-532, 2003.
 
14) Costantino JP, Gail MH, Pee D, et al:Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541-1548, 1999.
PubMed
15) Rockhill B, Spiegelman D, Byrne C, et al:Validation of the Gail et al; model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358-366, 2001.
PubMed
16) Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al:A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 87:190-197, 1995.
PubMed
17) Thomas HV, Key TJ, Allen DS, et al:A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 76:401-405, 1997.
PubMed
18) Miyoshi Y, Tanji Y, Taguchi T, et al:Association of Serum Estrone Levels with Estrogen Receptor-positive Breast Cancer Risk in Postmenopausal Japanese Women. Clin Cancer Res 9:2229-2233, 2003.
PubMed
19) Missmer SA, Eliassen AH, Barbieri RL, et al:Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856-1865, 2004.
PubMed
20) Miyoshi Y, Funahashi T, Kihara S, et al:Association of serum adiponectin leveis with breast cancer risk. Clin Cancer Res 9:5699-5704, 2003.
 
21) Mantzoros C, Petridou E, Dessypris N, et al:Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102-1107, 2004.
 
22) Baum M, Budzar AU, Cuzick J, et al:ATAC Trialists:Group, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breastcancer; first results of the ATAC randomised trial. Lancet 359:2131-2139, 2002.
 
23) Goss PE, Ingle JN, Martino S, et al:A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engi J Med 349:1793-1802, 2003.
 
24) Coombes RC, Hall E, Gibson LJ, et al:A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092, 2004.
PubMed
25) Lanza-Jacoby S, Miller S, Flynn J, et al:The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. Cancer Epidemiol Biomarkers Prev 12:1486-1491, 2003.
PubMed

VIII. 放射線療法

P.399 掲載の参考文献
1) Veronesi U, Saccozzi R, Del Vecchio M, et al:Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 305(1):6-11, 1981.
PubMed
2) Fisher B, Bauer M, Margolese R, et al:Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312(11):665-673, 1985.
PubMed
3) Morrow M, Strom EA, Bassett LW, et al:Standard for breast conservation therapy in the management of invasive breast carcinoma. CA Cancer J Clin 52(5):277-300, 2002.
PubMed
4) Morrow M, Strom EA, Bassett LW, et al:Standard for the management of ductal carcinoma in situ of the breast (DCIS). CA Cancer J Clin 52(5):256-276, 2002.
PubMed
5) Whelan T, Olivotto I, Levine M, et al:Clinical practice guidelines for the care and treatment of breastcancer:breast radiotherapy after breast-conserving surgery (summary of the 2003 update). CMAJ 168(4):437-439, 2003.
 
6) Huang J, Barbera L, Brouwers M, et al:Does Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review. J Clin Oncol 21(3):555-563, 2003.
PubMed
7) Wallgren A, Bernier J, Gelber RD, et al:Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancer. Int J Radiat Oncol Biol Phys 35(4):649-659, 1996.
PubMed
8) Buchholz TA, Hunt KK, Amosson CM, et al:Sequencing of chemotherapy and radiation in lymphnode-negative breast cancer. Cancer j Sci Am 5(3):159-164, 1999.
 
9) McCormick B, Norton L, TJ, et al:The impact of the sequence of radiation and chemotherapy onlocal control after breast-conserving surgery. Cancer J Sci Am 2(1):35-45, 1996.
 
10) Goffman TE:Hypofractionation Redux? J Clin Oncol 22:589-591, 2004.
PubMed
11) Romestaing P, Lehingue Y, Carrie C, et al:Role of a 10-Gy boost in the conservative treatment of early breast cancer:results of a randomized clinical trial in Lyon. J Clin Oncol 15(3):963-968, 1997.
 
12) Bartelink H, Horiot JC, Poortmans P, et al:Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345(19):1378-1387, 2001.
PubMed
13) Whelan T, Levine M, Julian J, et al:The Effects of Radiation Therapy on Quality of Life of Women with Breast Carcinoma. Cancer 88(10):2260-2266, 2000.
PubMed
14) Meric F, Buchholz TA, Mirza NQ, et al:Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol 9(6):543-549, 2002.
PubMed
15) Paszat LF, Mackillop WJ, Groome PA, et al:Mortality from myocardial infarction following post lumpectomy radiotherapy for breast cancer; a population-based study in Ontario. Int J Radiat Oncol Biol Phys 43(4):755-762, 1999.
 
16) Vallis KA, Pintilie M, Chong N, et al:Assessment of Coronary Heart Disease Morbidity and Mortality After Radiation Therapy for Early Breast Cancer. J Clin Oncol 20(4):1036-1042, 2002.
PubMed
17) Early Breast Cancer Trialists:collaborative Group:Effects of radiotherapy and surgery in early breast cancer; An overview of the randomized trials. N Engl J Med 333:1444-1455, 1995.
 
18) Overgaard M, Jensen MJ, Ocergaard J, et al:Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen; Danish Breast Cancer Cooperative Group DBCG 82 c randomized trial. Lancet 353:1641-1648, 1999.
 
19) Early Breast Cancer Trialists:collaborative Group:Favourable and unfavourable effects on longterm survival of radiotherapy for early breast cancer:An overview of the randomized trials. Lancet 355:1757-1770, 2000.
 
20) Ragaz J, Olivotto I, Spinelli J, et al:Locoregional radiation therapy in patients with high-risk breastcancer recieving adjuvant chemotherapy; 20 year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116-126, 2005.
 
21) Klefstrom P, Grohn P, Heinonen E, et al:Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. Cancer 60:936-942, 1987.
PubMed
22) Olson JE, Neuberg D, Pandya KJ, et al:The role of radiotherapy in the management of operable locally advanced breast cancer; results of a randomized trial by the Western Cooperative Oncology Group. Cancer 79:1138-1149, 1997.
 
23) Recht A, Edge SB, Solin LJ, et al:Postmastectomy radiotherapy; clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19(5):1539-1569, 2001.
 
24) Shenkier T, Weir L, Levine M, et al:Clinical practice guidelines for the care and treatment of breastcancer:15, Treatment for women with stage III or locally advanced breast cancer. CMAJ 170(6):983-994, 2004.
PubMed
25) Pierce LJ:The use of radiotherapy after mastectomy; a review of the literature. J Clin Oncol 23(8):1706-1717, 2005.
PubMed
26) Marks LB, Halperin EC, Prosnitz LR, et al:Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with≧10 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 23:1021-1026, 1992.
 
27) Lennvall-Nittby L, lengrup I, Landberg I, et al:The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial Acta Oncol 32:642-646, 1993.
 
28) Bromqqvist C, Tiusanen K, Elomaa I, et al:The combination of radiotherapy, adjuvant chemotherapy cyclophosphamide-doxorubicin-ftoraful and tamoxifen in stage II breast cancer:Long-term follow-up results of a randomized trial. Br J Cancer 66:1171-1176, 1992.
 
29) Katz A, Strom EA, Buchholz TA, et al:Loco-regional recurrence patterns after, mastectomy and doxorubicin-based chemotherapy; implications for postoperative irradiation. J Clin Oncol 18:2817-2827, 2000.
 
30) Pierce LJ, Butler JB, Martel MK, et al:Postmastectomy radiotherapy of the chest wall:dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys 52(5):1220-1230, 2002.
PubMed
31) Yu J, Li G, Li J, et al:The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields. Int J Radiat Oncol Biol Phys 61(3):874-878, 2005.
 
32) Larson D, Weinstein M, Goldberg I, et al:Edema of the arm as a function of the extent of axillary surgery in patients with stage III carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 12:1575-1582, 1986.
 
33) Bijker N, Rutgers EJT, Peters JL, et al:Low risk of locoregional recurrence of primary breast carcinoma after treatment with a modification of the Halsted radical mastectomy and selective use of radiotherapy. Cancer 85:1773-1781, 1999.
 
34) Lingos Tl, Recht A, Vicini F, et al:Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21:355-360, 1991.
 
35) Hrafnkelsson J, Nilddon K, Sonderberg M, et al:Tolerance of radiotherapy combined with adjuvant chemotherapy in breast cancer. Acta oncol 26:269-272, 1987.
 
36) Schweitzer VG, Juillard GJF, Bajada CL, et al:Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 76:1069-1072, 1995.
 
37) Hojris I, Overgaard M, Christensen JJ, et al:Morbidity and mortality of ischemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy:Analysis of DBCG 82 b and 82 c randomized trials. Lancet 354:1425-1430, 1999.
PubMed
38) Nixon AJ, Manola J, Gelman R, et al:No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques. J Clin Oncol 16:1374-1379, 1998.
 
39) Shapiro Cl, Hardenbergh PH, Gelman R, et al:Cardiac effects of adjuvant doxorubicin and radiationtherapy in node positive breast cancer patients. J Clin Oncol 16:3493-3501, 1998.
 
40) Zambetti M, Moliterni A, Materzazzo C, et al:Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicine and breast irradiation. J Clin Oncol 19:37-43, 2001.
 
41) Hardenbergh P, Recht A, Gollamudi S, et al:Treatment-related toxicity from a randomized trial of the sequencing of doxorubicin and radiation therapy in patients treated for early stage breast cancer. Int J Radiat Oncol Biol Phys 45:69-72, 1999.
PubMed
42) Pierce SM, Recht A, Lingos TJ, et al:Long-term radiation complications following conservative surgery and raditation therapy in patients with early stage breat cancer. Int J Radiat Oncol Biol Phys 23:915-923, 1992.
 
43) Pierce LJ:Treatment Guidelines and Techniques in Delivery of Postmastectomy Radiotherapy Management of Operable Breast Cancer. J Natl Cancer Inst Monography 30:117-124, 2001.
 
44) Neugut Al, Weingerg MD, Ahsan H, et al:Carcinogenic effects of radiotherapy for breast cancer. Oncology 13:1245-1256, 1999.
 
45) Neugut Al, Robinson E, Lee Wc, et al:Lung cancer after radiation therapy for breast cancer. Cancer 71:3054-3057, 1993.
 
46) Shapiro Cl, Recht A:Late effects of adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 16:101-112, 1994.
PubMed
47) Boice JD Jr, Harvey EB, Blettner M, et al:Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 326:781-785, 1992.
PubMed
P.409 掲載の参考文献
1) Wu JS, et al:Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastasis. Int J Radiat Oncol Biol Phys 55:594-605, 2003.
 
2) Falkmer U, et al:A systematic review of radiation therapy effects in skeletal metastasis. Acta Oncol 42; 620-633, 2003.
PubMed
3) 小口正彦, ほか:骨転移に対する緩和的放射線治療.がん看護7:12-15, 2002.
 
4) 中川恵一(編):放射線治療とEBM. インナービジョン, 東京, 2003.
 
5) Gasper L, et al:Recurslve partitioning analysls (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastasis trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997.
 
6) Weltman E, et al:Radiosurgery for brain metastasis; who may not benefit? Int J Radiat Oncol Biol Phys 51:1320-1327, 2001.
 

IX. 乳がん検診

P.417 掲載の参考文献
1) Koibuchi Y, lino Y, Takei H, et al:The effect of mass screening by physical examination combined with regular breast self-examination on clinical stage and course of Japanese women with breast cancer. Oncol Rep 5:151-155, 1998.
 
2) Kanemura S, Tsuji l, Ohuchi N, et al:A case control study on the effectiveness of breast cancer screening by clinical breast examination in Japan. Jpn J Cancer Res 90:607-613, 1999.
 
3) Kerlikowske K, Grady D, Rubin SM, et al:Efficacy of screening mammography:a meta-analysis. JAMA 273:149-154, 1995.
PubMed
4) Smart CR, Hendrick RE, Rutledge JH, et al:Benefit of mammography screening in women aged 40 to 49 years; current evidence from randomized controlled trials. Cancer 75:1619-1626, 1995.
PubMed
5) 大内憲明, 遠藤登喜子, 辻一郎, ほか:MG導入による乳癌検診の精度管理の確立に関する研究 (7-8). 厚生省がん研究助成金による研究報告. 平成8年度, pp101-106, 国立がんセンター, 東京, 1997.
 
6) Kolb TM, Lichy J, Newhouse JH:Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them:an analysis of 27,825 patient evaluations. Radiology 225:165-175, 2002.
PubMed
P.425 掲載の参考文献
1) Kanemura S, Tsuji I, Ohuchi N, et al:A case control study on the effectiveness of breast cancer screening by clinical breast examination in Japan. Jpn J Cancer Res 90:607-613, 1999.
PubMed
2) Shapiro S, Coleman A, Broeders M, et al:Breast cancer screening programs in 22 countries; current policies, administrations, and guidelines. Int J Epidemiol 27:735-742, 1998.
 
3) 厚生労働省平成15年度老人保健事業報告:がん検診. http://www.mhlw.go.jp/toukei/salkin/hw/c-hoken/03/kekka14.html
 
4) 大内憲明 (編):マンモグラフィによる乳がん検診の手引き. 精度管理マニュアル, 改訂第3版, 日本医事新報社, 東京, 2004.
 
P.434 掲載の参考文献
1) 久道 茂, ほか:新たながん検診手法の有効性の評価報告書. pp1-16, 日本衛生協会, 東京, 2001.
 
2) 園尾博司:乳がん検診の有用性. 性差と医療 1(2):153-157, 2004.
 
3) 岡崎邦泰, 山本泰久, 園尾博司, ほか:岡山県の新しい乳癌検診指針について. 日乳癌検診学会誌 14(2):129-135, 2005.
 
4) 園尾博司:乳癌早期発見における乳房自己検診の役割. 総合検診 31(1):200, 2004.
 
5) 西 敏夫, 古妻嘉一, 弥生恵司, ほか:乳癌検診に携わる保健婦・看護婦の検診に対する知識と関心度. 日乳癌検診学会誌 8(3):259-265, 1999.
 
6) Yoshida K, Abe R, Itoh S, et al:Comparison of interval breast cancers with other breast cancers detected through mass screening and in outpatient clinics in Japan. Jpn J Clin Oncol 20:374-379, 1990.
PubMed
7) 駒木幹正, 鎌村好孝, 田中克浩, ほか:中間期乳癌の特徴. 日乳癌検診学会誌 5(1):97-103, 1996.
 
8) 伊藤末喜, 吉田 貢, 泉 喜策:乳癌検診効果を上げるためのチェックポイント. 日乳癌検診 学会誌 3(2):183-188, 1994.
Medical*Online
9) Hackshaw AK, Paul EA:Breast self-examination and death from breast cancer:a metaanalysis. British J Cancer 88(7):1047-1053, 2003.
 
10) Harvey B, Miller A, Baines C, et al:Effect of breast self-examination techniques on the risk o death from breast cancer. CMAJ 157(9):1205-1212, 1997.
 
11) Mucut J, Huncharek M:Breast self-examination and extent of disease:a population-based study. Cancer Detect Prev 15(2):155-159, 1991.
 
12) Newcomb PA, Weiss NS, Storer BE, et al:Breast self-examination in relation to the occurrence of advanced breast cancer. J Natl Cancer Inst 83:260-265, 1991.
 
13) 深尾 彰, 柴田亜希子, 高橋達也:我が国におけるこれまでの老人保健事業等の評価, 検討及び関連する医療福祉分野の施策・研究に関する調査研究-がん検診-報告書. pp 31-42, 日本公衆衛生協会, 東京, 2002.
 
14) Holmberg L, Ekbom A, Calle E, et al:Breast cancer mortality in relation to self-reported use of breast self-examination; A cohort study of 450,000 women. Breast Cancer Res Treat 43(2):137-140, 1997.
PubMed
15) Gastrin G, Miller A, To T, et al:Incidence and mortality from breast cancer in the Mama Program for breast screening in Finland, 1973-1986. Cancer 73(8):2168-2174, 1994.
PubMed
16) Semiglazov VF:Study of the role of breast self-examination in the reduction of mortality from breast cancer. Eur J Cancer 29 A (14):2039-2046, 1993.
 
17) Semiglazov VF, et al:The role of breast self-examination in early breast cancer detection. Eur J Epidemiol 8:498-502, 1992.
PubMed
18) Thomas DB, Gao DL, Ray RM, et al:Randomized trial of breast self-examination in Shanghai; Final results. JNCI 94:1445-1457, 2002.
PubMed
19) 園尾博司, 崔 哲洵, 前崎茂子:乳房の自己検診. 外科54(6):574-581, 1992.
 

X. 乳癌診療におけるインフォームド・コンセント

P.446 掲載の参考文献
1) 大城 孟:説明から会話 (対話)へ (その1). 日本医事新報 4184:75-80, 2004.
 
2) 乳房温存療法のガイドライン「標準的な乳房温存療法の実施要綱の研究」班に基づく治療指針. 2005.
 
3) 日本乳癌学会 (編):科学的根拠に基づく乳癌診療ガイドライン. 1. 薬物療法, 金原出版, 東京, 2004.
 
4) 「がんの社会学」に関する合同研究班:がん体験者の悩みや負担等に関する実態調査報告書 概要版. がんと向き合った 7, 885人の声, 2004.
 
5) 光山昌珠:乳癌治療におけるインフォームドコンセント. 別冊 医学の歩み, pp 489-491, 医歯薬出版, 東京, 2004.
 
P.453 掲載の参考文献
1) 池田雅彦, 園尾博司:セカンドオピニオン. 臨床と研究79:427-430, 2002.
 
2) 吉田 聡,三上八郎 (編):セカンドオピニオン. 現代のエスプリ (NO 416), pp1-196, 至文堂, 東京, 2002.
 
3) 平田公一:セカンドオピニオンを求められた時にどう対応すればよい? 乳腺診療TIPS&TRAPS 7:4-5, 2002.
 
4) 吉田 聡,三上八郎:セカンドオピニオン. 治療83 (増):443-448, 2001.
 
5) 伊藤園明:科学療法におけるセカンドオピニオン. 看護実践の科学 5:63-67, 2005.
 
P.460 掲載の参考文献
1) Saeki T, et al:A Japanese phase I study of continuous oral capecitabine in patients with malignant solid tumor. Int J Clin Oncol 10:51-57, 2005.
PubMed
2) Kusama M, et al:A phase II study of xeloda (capecitabine) in patients with advanced/metastatic breast carcinoma; The cooperative study group of capecitabine for breast carcinoma. Proc ASCO 20:44b (abst 1924), 2001.
 
3) Nobholtz JM, et al:Anastrozl (ArimidexTM) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:survival analysis and updated safety results. Eur J Cancer 39(12):1684-1689, 2003.
 
4) ATAC Trialists:Group:Results of ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years:adjuvant treatment for breast cancer. Lancet 365:60-62, 2005.
 
P.466 掲載の参考文献
1) Royal college of Obstericians and Gynaecologists, Pregnancy and Breast Cancer Guideline No. 12. Revised January 2004.
 
2) SOGC clinical practice guidelines. J Obstet Gynaecol Can 24:164-180, 2002.
PubMed
3) Up To Date version 13. 1, 2005.
 
4) 厚生労働科学研究費補助金 (H14-医療-064) 研究報告書. 2003.
 
5) 科学的根拠に基づく乳癌診療ガイドライン 薬物療法. 2004年版.
 
6) 伊藤良則, 戸井雅和 (編):医学のあゆみ. 乳腺疾患state of arts, 医歯薬出版, 東京, 2004.
 
P.471 掲載の参考文献
1) 岩佐 弘一:ガイドライン外来診療2004. 更年期障害:190-197, 2004.
 
2) Writing Group for the Women's Health Initiative Investigators:Risks and benefits of estrogen plus progestins in healthy postmenopausal women; principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:366, 2002.
 
3) The Women's Health Initiative Steering Committee:Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291:1701-1712, 2004.
 
4) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350:1047-1059, 1997.
 
5) Agenes F, Franco B, Elio R, et al:Breast cancer risk in relation to different types of hormone replacement therapy in the E 3 N-EPIC cohort. Int J Cancer 114:448-454, 2005.
 
6) Claudia S, Anette T P, Elsebeth L, et al:Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721-727, 2004.
 
7) Biglia N, Defabiani E, Ponzone R, et al:Management of risk of breast carcinoma in postmenopausal women. Endocrine-Related Cancer 11:69-83, 2004.
PubMed
9) Marchbanks PA, McDonald JA, Wilson HG, et al:Oral contraceptives and the risk of breast cancer. New England Journal of Medicine 346:2025-2032, 2002.
PubMed

XI. チーム医療と緩和ケア

P.480 掲載の参考文献
1) Pinder KL, Ramirez AJ, Richards AMA, et al:Cognitive responses and psychiatric disorder in women with operable breast cancer. Psycho-oncology 3:39-46, 1994.
 
2) Massie MJ, Holland JC:Overview of normal reactions and prevalence of psychiatric disorders. Handbook of psychooncology, 1st ed, Holland J, Rowland JH (eds), pp 273-282, Oxford University Press, New York, 1990 (河野博臣, 濃沼信夫, 神代尚芳 (監訳) :サイコオンコロジー(2). 第1版, pp3-11, メディカルサイエンス社, 東京, 1993).
 
3) 大野真司:乳癌患者と家族のケア. 先端医療シリーズ21 乳癌の最新医療, pp 377-381, 先端医療技術研究, 東京, 2003.
 
4) 片岡明美, 大野真司, 大島 彰:チーム医療:患者と家族が求める医療遂行のためのシステム構築. 乳癌の臨床 19:441-447, 2004.
Medical*Online
5) Greenhalgh T, Haurwitz B (eds):Narrative Based Medicine; Dialogue and discourse in Clinical Practice. BMJ Books, London, 1998.
 
P.487 掲載の参考文献
1) 恒藤 暁:末期がん患者の特徴. 最新緩和医療学, 第1版, pp11-24, 最新医学社, 大阪, 1999.
 
2) 吉澤明孝, 石黒 徹:臭いの管理. ターミナルケアII (suppl):239-241, 2001.
 
3) 堀 泰祐:乳癌患者支援活動. 緩和医療学5(1):41-46, 2003.
 
P.493 掲載の参考文献
1) Holland JC, Rawland JH:Handbook of Psychooncology. Oxford University Press, New York, 1990.
 
2) Derogatis LR:The prevalence of psychiatric disorders among cancer patients. JAMA 249:751-757, 1983.
PubMed
3) Uchitomi Y, Mikami l, Kugaya A, et al:Depression after successful treatment for nonsmall cell lung cancer; A 3-month follow-up study. Cancer 89:1172-1179, 2000.
 
4) Akechi T, Okamura H, Nishiwaki Y, et al:Psychiatric disorders and associated and predictive factorsin patients with unresectable nonsmall cell lung carcinoma; Alongitudinal study. Cancer 92:2609-2622, 2001.
 
5) Kugaya A, Akechi T, Okuyama T, et al:Prevalence, predictive factors, and screening of psychological distress in patients with newly diagnosed head and neck cancer. Cancer 88:2817-2823, 2000.
PubMed
6) Akechi T, Okuyama T, Imoto S, et al:Biomedical and psychosocial determinants of psychiatric morbidity among postoperative ambulatory breast cancer patients. Breast Cancer Res Treat 65:195-202, 2001.
PubMed
7) Okamura H, Watanabe T, Narabayashi M, et al:Psychological distress following first recurrence of disease in patients with breast cancer; prevalence and risk factors. Breast Cancer Res Treat 61:131-137, 2000.
PubMed
8) Chochinov HM, Wilson KG, Enns M, et al:Desire for death in the terminally ill. Am J Psychiatry 152:1185-1191, 1995.
PubMed
9) Foley KM:The treatment of cancer pain. N Engl L Med 313:84-95, 1985.
 
10) Minagawa H, Uchitomi Y, Yamawaki S, et al:Psychiatric morbidity in terminally ill cancer patients:A prospective study. Cancer 78:1131-1137, 1996.
PubMed
11) Chochinov HM, Wilson KG, Enns M, et al:"Are you depressed?" Screening for depression in theterminally ill. Am J Psychiatry 154:674-676, 1997.
 
12) Bruera E, Miller L, McCallion J, et al:Cognitive failure in patients with terminal cancer:a prospective study. J Pain Symptom Manage 7:192-195, 1992.
 
13) Greer S, Morris T, Pettingale KW:Psychological response to breast cancer:effect on outcome. Lancet 13:785-787, 1979.
 
14) Pettingale KW, Morris T, Greer S, et al:Mental attitudes to cancer; an additional prognostic factor. Lancet 30:750, 1985.
 
15) Watson M, Haviland JS, Greer S, et al:Influence of psychological response on survival in breastcancer:a population-based cohort study. Lancet 16:1331-1336, 1999.
 
16) Spiegel D, Bloom JR, Kraemer HC, et al:Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 14:888-891, 1989.
 
17) Goodwin PJ, Leszcz M, Ennis M, et al:The effect of group psychosocial support on survival in metastatic breast cancer. N Engl J Med 345:1719-1726, 2001.
PubMed
18) Fukui S, Kugaya A, Okamura H, et al. A psychosocial group intervention for Japanese women with primary breast cancer; a randomized controlled trial. Cancer 89:1026-1036, 2000.
PubMed
19) Chujo M, Mikami l, Takashima S, et al:A feasibility study of psychosocial group intervention for breast cancer patients with first recurrence. Support Care Cancer 13:503-514, 2005.
 
P.502 掲載の参考文献
1) World Health Organization (WHO):National cancer control programmes:policies and managerial guidelines. 2nd ed, pp 83-84, WHO, Geneva 2002.
 
2) 安達 勇:緩和医療におけるチーム医療の重要性. Pharma Medica 20:75-79, 2002.
Medical*Online
3) 有田英子, 花岡一雄:急性痛・慢性痛の治療とその問題点. 疼痛治療の現状と展望, 花岡一雄, 土肥修司 (監修), pp13-37, ミクス, 東京, 1998.
 
4) Zech DF, et al:Validation of World Health Organization Guidelines for cancer pain relief; a 10-year prospective study. Pain 63:65-75, 1995.
PubMed
5) World Health Organization:Cancer Pain Releif. pp 7-70, WHO, Geneva, 1986.
 
6) 森本昌広:非ステロイド抗炎症薬ペインクリニックで用いる薬, 小川節郎 (編), pp15-27, 真興交易医学出版部, 東京, 2002.
 
7) 森田達也, ほか:ターミナルケア. 鎮痛補助薬としてのステロイド 5:267-270, 1995.
 
8) 加藤 実:拮抗性鎮痛薬. ペインクリニックで用いる薬, 小川節郎 (編), pp15-27, 真興交易医学出版部, 東京, 2002.
 
9) 篠道 弘, ほか:癌疼痛治療を目的としたモルヒネ持続皮下注時におけるレスキュードースとしての早送りの有効性と安全性の検討. 医療薬学 31:559-562, 2005.
 
10) Laird D:Paradoxical pain. Lancet 341:241, 1993.
PubMed
11) 小穴正博:高齢癌患者に対するモルヒネ投与量の検討. 死の臨床 16:191, 1993.
 
12) 高宮有介, ほか:モルヒネ持続皮下注入法の実際. 臨床と薬物治療 9:1077-1081, 1990.
 
13) Chabal C, et al:The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiology 76:513-517, 1992.
PubMed
14) Chong S, et al:Pilot study evaluating local anesthetics administered systemically for treatment ofpain in patients with advanced cancer. J Pain and Sym Management 13:112-117, 1997.
 
15) McQuary H, et al:Anticonvulsant drugs for management of pain; A systematic review. Br Med J 311:1047-1052, 1995.
 
16) Botney M, Fielfs HC:Amitriptyline potentiates morphine analgesia by direct action on the centralnervous system. Ann Neurol 13:160-164, 1983.
 
17) Max MB, Byas-Smith MG, Gracely RH, et al:Intravenous infusion of the NMDA antagonist, ketamine, in chronic post-traumatic pain and allodynia:A double-blind comparison to alfentanil, and placebo. Clin Neuropharmacol 18:360-368, 1995.
 
18) 国立がんセンター (監修):「痛み止めの薬」のやさしい知識.pp1-40, 財団法人がん研究振興財団, 東京, 2004.
 
19) United States Pharmacipial Convention, Inc.:Naloxone, USP DI, 1, pp 1980-1982, 1994.
 
20) 塩酸ナロキソン注射液・添付文書, 小玉, 東京, 1990.
 
21) Indelicato RA, Portenoy RK:Opioid Rotation in the Management of Refractory cancer pain. J C oncol 20:348-352, 2002.
 
22) Bruera E, MacEachern, Ripamonti C, et al:Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 119:906-907, 1993.
PubMed
23) Bianchi A, et al:Central control of breathing in mammals; neuronal circuitry, membrane properties, and neurotransmitters. Physiological Reviews 75:1-45, 1995.
PubMed
24) Allard P, Lamontagne C, Bernard P, et al:How effective are supplementary dose of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage 17:256-265, 1999.
PubMed
25) American Society of Clinical Oncology:Optimizing Cancer Care-The Importance of Symptom Management, Dyspea, 2001.
 
26) Smoller JW, Pollack MH, Otto MW, et al:Panic anxiety, and respiratory disease; Theoretical andclinical considerations. Am J Respir Crit Care Med 154:6-17, 1996.
 
27) Ripamonti E, Twycross R, Baines M, et al:Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer 9:223-233, 2001.
 

XII. 病期分類および治療効果判定

P.511 掲載の参考文献
1) Sobin LH, Wittekind Ck (eds):TNM CIassification of Malignant Tumors. 6th ed, UICC, Wiley-Liss Publication, NewYork, 2002.
 
2) 日本乳癌学会 (編):臨床・病理. 乳癌取扱い規約, 第15版, 金原出版, 東京, 2004.
 
3) Therasse P, Arbuck SG, Eisenhauer EA, et al:New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:2-5-216, 2000.
 
4) 小林俊三, 田中宏紀, 呉山泰進, ほか:WHOの固形癌治療効果判定基準はどう変わろうとしているか. 名古屋市立病院紀要 22:73-75, 1999.
 

XIII. 特別企画

P.525 掲載の参考文献
1) 笠原善郎, 関口令安, 斎藤光江:クリニカルパス. 乳癌治療のコツと落とし穴. 第1版, 霞富士雄 (編), pp 41-47. 中山書店, 東京, 2004.
 
2) 青儀健二郎, 佐伯俊昭, 大住省三:乳癌診療用クリニカルパスを中心にしたインフォームドコンセント効率的取得のための工夫専門医に学ぶ乳癌治療のインフォームドコンセント, 第1版. 佐野宗明 (編), pp 61-82, 金原出版, 東京, 2004.
 
3) 袴田健一, 佐々木睦男:DPCとクリティカルパス. 癌と化学療法 31:1179-1185, 2004.
Medical*Online
P.529 掲載の参考文献
1) Eddy DM:Clinical decision making:from theory to practice; Designing a practice policy; Standards, guidelines and options. JAMA 263(22):3077-3082, 1990.
PubMed
2) 福井次矢, 丹後俊郎:ガイドラインの作成の手順. EBMジャーナル4(3):28-36, 2003.
 
3) Oxford Center for Evidence-Based Medicine Levels of Evidence. May 2001:http//www,cebm.net/
 
4) 日本乳癌学会:科学的根拠に基づく乳癌診療ガイドライン. 1. 薬物療法, 2004年度版, p10, 金原出版, 東京, 2004.
 
P.534 掲載の参考文献
1) 富永祐民, 黒石哲生:乳癌の疫学的動向. 日本臨床58(増刊号):5-11, 2000.
 
2) Oshima A, Ajiki W, Tanaka H, et al:Significance and usefulness of cancer registries. Int Clin Oncol 3:343-350, 1998.
 
3) 大島 明, 黒石哲生, 田島和雄 (編):がん統計白書-罹患/死亡/予後-2004, pp1-306, 篠原 出版新社, 東京, 2004.
 
4) Howe HL, Wingo PA, Thun MJ, et al:Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93(11):824-842, 2001.
 
5) 森本忠興, 遠藤登喜子, 小田切邦雄:マンモグラフィ検診における精度管理委員会の役割. 日乳癌検診学会誌 9(1):25-30, 2000.
 
6) 森本忠興, 遠藤登喜子, 岡崎正敏:乳癌検診におけるマンモグラフィ検診精度管理中央委員会の役割. 日本醫事新報 4005:37-42, 2001.
Medical*Online
7) マンモグラフィ検診精度管理中央委員会:マンモグラフィ検診精度管理中央委員会の役割について. 日乳癌検診学会誌 10(1):71-87, 2001.
 
8) 岡崎正敏,石栗一男, 今村恵子, ほか:マンモグラフィ検診精度管理中央委員会 (精中委) ・施設画像評価委員会の活動状況. 日本がん検診・診断学会誌 10(2):176-182, 2003.
 
9) Tadaoki M, Masatoshi O, Tokiko E:Current Status and Goals of Mammographic Screening for Breast Cancer in Japan. Breast Cancer 11(1):73-81, 2004.
 
10) 今村恵子, 寺田 央, 岡崎正敏, ほか:マンモグラフィ実施機関についての施設認定. 新医療:2-5, 2004.
 
11) マンモグラフィ検診精度管理中央委員会:マンモグラフィ検診精度管理中央委員会報告書 (第1版) ; 平成10年度～13年度の活動状況. 2001.
 
12) マンモグラフィ検診精度管理中央委員会:マンモグラフィ検診精度管理中央委員会報告書 (第2版):平成14年度～15年度の活動状況. 2004,
 
13) 森本忠興, 葉久真理:マンモグラフィ検診による乳癌死亡滅少効果とわが国の現状と展望. 日本放射線技術学会誌, 2005 (印刷中).
 
14) 精度管理マニュアル作成に関する委員会監修, 大内憲明 (編):マンモグラフィによる乳がん検診の手引き; 精度管理マニュアル. 改訂3版, pp1-195, 日本醫事新報社, 東京, 2004.
 
15) 日本医学放射線学会/日本放射技術学会マンモグラフィガイドライン委員会 (編):マンモグラフィガイドライン (第2版). 医学書院, 東京, 2004.
 
P.540 掲載の参考文献
1) 濃沼信夫 (主任研究者):厚生労働科学研究費補助金第3次対がん総合戦略研究事業「がん医療経済と患者負担最小化に関する研究」平成16年度報告書. 2005.
 
2) 濃沼信夫 (主任研究者):厚生労働科学研究費補助金がん克服戦略研究事業「がん医療経済とその研究基盤の整備に関する研究」平成15年度報告書. 2004.
 
3) 濃沼信夫, 並木俊一:QOL評価に必要な医療経済学の視点. Urology View 2(2):14-21, 2004.
Medical*Online
4) 濃沼信夫:がん予防・治療の医療経済. からだの科学 228:13-18, 2003.
 
P.545 掲載の参考文献
1) 厚生労働省:医療・介護関係事業者における個人情報の適切な取扱いのためのガイドライン. 厚生労働省ホームページ:厚生労働分野における個人情報の適切な取扱いのためのガイドラインなど (http://www.mhlw.go.jp/topics/bukyoku/seisaku/kojin/index.htm)
 
2) 遺伝医学関連10学会:遺伝学的検査に関するガイドライン. 日本人類遺伝学会ホームページ:参考資料 (http://jshg.jp/)
 
3) Young ID:Cancer Genetics. Introduction to risk calculation in genetic counseling, 2 nd ed, pp 122-132, Oxford University Press, New York, 1999.
 
4) 新井正美, 宇都宮譲二:家族性乳癌における遺伝子検査のためのインフォームドコンセント. 別冊医学のあゆみ乳腺疾患:492-496, 2004.
 
5) American Society of Clinical Oncology:American Society of Clinical Oncology policy statement update:genetic testing of cancer susceptibility. Journal of Clinical Oncology 21:2397-2406, 2003.
 
6) Arai M, Utsunomiya J, Miki Y:Familial breast and ovarian cancers. International Journal of Clinical Oncology 9:270-282, 2004.
PubMed
7) 岡村 仁:がんの遺伝カウンセリング. 臨床精神医学33:693-697, 2004.
 
8) Sattin RW, Rubin GL, Webster LA, et al:Family history and the risk of breast cancer. JAMA 253:1908-1913, 1985.
PubMed
9) WHO:Review of Ethical Issues in Medical Genetics (検査結果の開示および守秘. 遺伝医学における倫理的諸問題の再検討). 日本人類遺伝学会会員有志 (翻訳), 松田一郎 (監修). pp 53-64, 遺伝医学セミナー実行委員会, 信州大学医学部社会予防医学講座, 2002.
 
P.549 掲載の参考文献
1) 渥美和彦:JACTは今後, 何をすべきか? JACT 1:5-6, 2005.
 
2) Lamson DW, Brignall MS:Antioxidants in cancer therapy I their actions and interactions with oncologic Therapies. Altern Med Rev 4:304-329, 1999.
PubMed
3) 米国対がん協会 (著):「がん」になってからの食事療法; 米国がん協会の最新ガイド. 坪野吉孝 (訳・解説), 法研, 東京, 2002.
 
4) Yamamoto S, Sobue T, Kobayashi M, et al; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group:Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst 95:906-913. 2003.
PubMed
5) Baum M, Budzar AU, Cuzick J, et al; ATAC Trialists:Group:Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer; first results of the ATAC randomised trial Lancet 359:2131-2139, 2002.
PubMed
6) Hyodo I, Amano N, Eguchi K, et al:Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23:2645-2654, 2005.
PubMed
7) DiGianni LM, Garber JE, Winer EP:Complementary and alternative medicine use among women with breast cancer. J Clin Oncol 20(18 Suppl):34 S-38 S, 2002.
 
8) Weiger WA, Smith M, Boon H, et al:Advising patients who seek complementary and alternative medical therapies for cancer. Ann Intern Med 137:889-903, 2002.
PubMed

書評

最近チェックした商品履歴

Loading...